<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01//EN" "http://www.w3.org/TR/html4/strict.dtd">
<!--
-->
<!-- %html{'xmlns'=>'http://www.w3.org/1999/xhtml', 'xml:lang'=>'en', 'lang'=>'en'} -->
<html>
<head>
<script type="text/javascript">window.NREUM||(NREUM={});NREUM.info={"beacon":"beacon-1.newrelic.com","errorBeacon":"jserror.newrelic.com","licenseKey":"d64d3db899","applicationID":"125361","transactionName":"dAkNQBFbXFUEREkBCVQTDlENQB9dDlUTCANZEkxHC1tH","queueTime":0,"applicationTime":11162,"ttGuid":"","agentToken":null,"agent":"js-agent.newrelic.com/nr-298.min.js","extra":""}</script>
<script type="text/javascript">window.NREUM||(NREUM={}),__nr_require=function a(b,c,d){function e(f){if(!c[f]){var g=c[f]={exports:{}};b[f][0].call(g.exports,function(a){var c=b[f][1][a];return e(c?c:a)},g,g.exports,a,b,c,d)}return c[f].exports}for(var f=0;f<d.length;f++)e(d[f]);return e}({"4O2Y62":[function(a,b){function c(a,b){var c=d[a];return c?c.apply(this,b):(e[a]||(e[a]=[]),void e[a].push(b))}var d={},e={};b.exports=c,c.queues=e,c.handlers=d},{}],handle:[function(a,b){b.exports=a("4O2Y62")},{}],YLUGVp:[function(a,b){function c(){var a=m.info=NREUM.info,b=m.proto="https"===l.split(":")[0]||a.sslForHttp?"https://":"http://";if(a&&a.agent&&a.licenseKey&&a.applicationID){f("mark",["onload",e()]);var c=h.createElement("script");c.src=b+a.agent,h.body.appendChild(c)}}function d(){"complete"===h.readyState&&f("mark",["domContent",e()])}function e(){return(new Date).getTime()}var f=a("handle"),g=window,h=g.document,i="readystatechange",j="addEventListener",k="attachEvent",l=(""+location).split("?")[0],m=b.exports={offset:e(),origin:l};h[j]?(h[j](i,d,!1),g[j]("load",c,!1)):(h[k]("on"+i,d),g[k]("onload",c)),f("mark",["firstbyte",e()])},{handle:"4O2Y62"}],loader:[function(a,b){b.exports=a("YLUGVp")},{}]},{},["YLUGVp"]);</script>
<title>
Kuhn v. Wyeth, Inc., 686 F.3d 618 (8th Cir. 2012), Court Opinion - Bloomberg Law 

</title>
<meta content='NOINDEX, NOFOLLOW' name='ROBOTS'>
<meta content='telephone=no' name='format-detection'>
<meta content='BLAW' name='apple-mobile-web-app-title'>
<meta name="csrf-param" content="authenticity_token"/>
<meta name="csrf-token" content="NiJ+70&#47;qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA="/>
<script src="/min_assets/framework.js?1389213936" type="text/javascript"></script>

<script src="/javascripts/daterange.js?1380743058" type="text/javascript"></script>
<script src="/javascripts/document/document.js?1382459272" type="text/javascript"></script>
<script src="/javascripts/document/document_viewer.js?1383685414" type="text/javascript"></script>
<script src="/javascripts/document/bciteutils.js?1388683076" type="text/javascript"></script>
<script src="/javascripts/jquery/jquery.query.js?1342203941" type="text/javascript"></script>
<script src="/javascripts/browser/browser.js?1387565892" type="text/javascript"></script>
<script src="/javascripts/document/image_viewer.js?1366129555" type="text/javascript"></script>
<script src="/javascripts/jquery/jquery.selection.js?1375450295" type="text/javascript"></script>
<script src="/javascripts/jquery/jquery.bb-copywithcitation.js?1383771008" type="text/javascript"></script>
<script src="/javascripts/document/copy_with_cite.js?1382560939" type="text/javascript"></script>
<script src="/javascripts/document/notepad.js?1366310522" type="text/javascript"></script>

<link href="/stylesheets/yui2/yui2_combo.css?1288273584" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/document_v2.css?1391022004" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/min_assets/framework.css?1391022047" media="screen,print" rel="stylesheet" type="text/css" />
<!--[if IE]>
<link href="/stylesheets/ie.css?1391022010" media="screen,print" rel="stylesheet" type="text/css" />
<![endif]-->
<link href="/stylesheets/search/search_results.css?1391022036" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/document.css?1391022003" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/document_viewer.css?1391022005" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/search/tree_view.css?1391022037" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/browser/browser_enhanced.css?1391021984" media="print,screen" rel="stylesheet" type="text/css" />
<style type='text/css'>
#content_document, #content_document h1, #content_document h2, #content_document h3, #content_document h4, #content_document h5, #content_document h6 { font-family:Times New Roman, Times, serif; }
				#content_document pre {
				white-space: pre-wrap;
				white-space: -moz-pre-wrap;
				white-space: -pre-wrap;
				white-space: -o-pre-wrap;
				word-wrap: break-word;
				font-family: Bloomberg Fixed 2 Unicode;
			}
			
			#content_document .page_no { 
				font-weight:bold;
				text-decoration:none;
			}
			
			#content_document .highlight { 
				font-weight:bold; 
				background-color:yellow; 
				color:black;
			}
			
			#content_document .bcitehi { 
				font-weight:bold; 
				background-color:violet; 
				color:black;
			}
			
			/*.UNICODE {
			}
			
			#content_document blockquote {
			}
			
			#content_document em {
			}   
			
			#content_document .tableofcontents {
			}
			
			#content_document div.blockgroup {
			}
			
			#content_document p.opinion_text {
			}  */
			
			#content_document, #content_document h1, #content_document h2, #content_document h3, #content_document h4, #content_document h5, #content_document h6, #content_document p, #content_document li, #content_document td, #content_document th, #content_document div {
				font-size: 11pt;
			}
			
			#content_document .main {
				text-align:center; 
				font-weight:bold; 
				color:black;
			}
			
			#content_document .ftnote { 
				font-style:italic;
			}
			
			#content_document .headline {
				font-weight:bold; 
				color:black;
			} 
			
			#content_document p.group{
				padding-top: 0; 
				padding-bottom: 1px; 
				padding-left: 0; 
				padding-right: 0;
				margin-top: 0; 
				margin-bottom: 1px; 
				margin-left: 0; 
				margin-right: 0;
			}
			
			#content_document .big {
				font-size: 13pt;
			}
			
			#content_document .indent {
				text-indent:2.5em;
			}
			
			#content_document .level2 {
				margin-left:2.5em;
				margin-right:2.5em;
			} 
			
			#content_document .level3 {
				margin-left:5em;
				margin-right:5em;
			} 					
			
			#content_document .level4 {
				margin-left:7.5em;
				margin-right:7.5em;
			} 					
			
			#content_document .level5 {
				margin-left:10em;
				margin-right:10em;
			} 					
			
			#content_document .level6 {
				margin-left:12.5em;
			} 					
			
			#content_document a.sup {
				font-size: 6pt; 
				vertical-align: top;
			}
			
			#content_document a.sup1 {
				font-size: 8pt; 
				vertical-align: top;
			}
			
			#content_document em.italic {
				font-style: italic;
			}
			
			#content_document em.bold {
				font-weight: bold;
				font-style: normal;
			}
			
			#content_document em.bold-big {
				font-size: 13pt; 
				font-weight: bold;
			}
			
			#content_document em.underline {
				font-style:normal; 
				text-decoration: underline;
			}
			
			#content_document em.bold-ital {
				font-weight: bold; 
				font-style: italic;
			}
			
			#content_document em.bold-underline {
				font-weight: bold; 
				text-decoration: underline;
			}
			
			#content_document em.ital-underline {
				font-style: italic; 
				text-decoration: underline;
			}
			
			#content_document em.ital-bold-underline { 
				font-style: italic; 
				font-weight: bold; 
				text-decoration: underline;
			}
			
			#content_document em.small-cap {
				font-style:normal; 
				font-variant: small-caps;
			}
			
			#content_document em.strike {
				font-style: normal;
				text-decoration: line-through;
			}
			
			#content_document .small-cap {
				font-style:normal; 
				font-variant: small-caps;
			}
			
			#content_document h1.organization {
				font-weight: bold; 
				text-align:center; 
				font-style: normal;
			} 
			
			#content_document h2.organization {
				font-weight: bold; 
				text-align:left;
				margin-left:2.5em; 
				margin-right:2.5em;
			}
			
			#content_document h3.organization {
				font-weight: bold; 
				text-align:left;
				margin-left:5em; 
				margin-right:5em;
			}
			
			#content_document h4.organization {
				font-weight: bold;
				text-align:left;
				margin-left:7.5em; 
				margin-right:5em;
			}
			
			#content_document h5.organization {
				font-weight: bold; 
				text-align:left;
				margin-left:10em; 
				margin-right:5em;
			}
			
			#content_document h2.citation {
				font-weight: bold; 
				text-align:left;
			}
			
			#content_document div.blcitation {
				font-size: 7pt; 
				text-align:center;
			}
			
			#content_document .italic {
				font-style:italic;
			}	
			
			#content_document ul.dash {
				list-style-type: none;
			}
			
			#content_document ul.bullet {
				list-style-type: disc;
			}
			
			#content_document ul.none {
				list-style-type: none;
			}
			
			#content_document li.off {
				list-style-type: none; 
			}
			
			#content_document .mypre { 
				font-size: 100%;
			}
			
			#content_document .TOC {
				text-align:left;  
				padding:5px;  
				margin:0 auto;  
				color: #000000;  
				font-weight: 500;
			}
			
			#content_document .TOC hr { 
				color:#339999;  
				background-color:#339999;  
				width:100%;  
				clear: both;  
				border: none;
			}
			
			#content_document .bluehr { 
				color:#339999;  
				background-color:#339999;  
				width:100%;  
				clear: both;  
				border: none;
			}
			
			#content_document .headinga { 
				color: #339999;   
				font-size: 20px;
				font-weight: 500;
				text-align: center;
			}
			
			#content_document .tocentry {
				text-indent:-18px;
				padding-left:18px;
				color: #003399;
				font-weight: 700;
			}
			
			#content_document .doctext {  
				margin:0 auto;  
				text-align: left;  
			}				 
			
			#content_document span.PAGE { 
				color: black; 
				font-weight: bold 
			}
			
			#content_document a:link {  	
				color: #003399;  
				font-weight: 700;
			}
			
			#content_document a:visited {  
				color: #660066;   
				font-weight: 700;
			}
			
			#content_document .fn{  
				padding-left: 50 px; 
				font-weight: 550;
			}				
			
			#content_document .fr a:link {  
				color: #003399;  
				font-weight: 600;
			}
			
			#content_document .fr a:visited {  
				color: #660066;  
				font-weight: 600;
			}
			
			#content_document .headinga { 
				color: #339999;   
				font-size: 20px;
				font-weight: 600;
				text-align: center;
			}
			
			#content_document .volume {  
				text-align:center;  
				padding:5px;  
				margin:0 auto;  
				color: #000000;  
				font-weight: 500;
			}				
			
			#content_document h2.blcitation {
				font-size: 7pt; 
				text-align:center; 
				white-space:nowrap;
			}
			
			#content_document cite.blcitation {
				white-space:nowrap;
			}
			
			#content_document table.page_legend { 
					width: 100px; 
					text-align: left; 
					background-color: white; 
					font-family: Bloomberg Proportional Unicode;
					font-size: 12px
			}
			#content_document div.page_text {  padding-left: 50 px; margin:0 0 0 50px;  text-align: center;  width:100px; font-size: 12px}

			#content_document .smalllinks{  text-align: right;  font-size: 10px;  font-weight: 500;}		
			
			#content_document .opinion_headnotes{
				margin-top:6px;
				margin-bottom:6px;
			}
			
			#content_document .headnote_group{
				padding: 10px 10px 2px 10px;
				background-color: #ECECEC;
				margin-top:4px;
				margin-bottom:10px;
			}
			
			#content_document .headnote_group_header{
				font-weight: bold;
				margin-bottom: 8px;
			}
			
			#content_document .opinion_headnote{
				clear:both;
				padding-bottom: 4px;
				margin-bottom:10px;
			}
			
			#content_document .highlighted_headnote{
				background-color: #FFFF22;
			}
			
			#content_document .headnote_link{
				font-weight:bold;
				text-decoration: none;
			}
			
			#content_document .show_hide_headnotes{
			}
			
			#content_document .clearfix:after {
				clear:both;
				content: ".";
				height:0px;
				display:block;
				visibility:hidden;
			}
			
			/* BNA Headnotes */
			
			#content_document .headnotesContainer {
				margin: 12px 0;
				padding: 12px 0;
				border-top: 1px solid #000;
				border-bottom: 1px solid #000;
			}
			
			#content_document .headnotesContainer .headnotesContainerTitle {
				font-size: 16px;
				font-weight: bold;
				text-align: center;
			}
			
			#content_document .headnotesContainer .headnoteTitle {
				padding: 8px 12px;
				background-color: #dedede;
				margin: 24px 0 0 0;
				font-size: 16px;
				font-weight: bold;
				text-transform: uppercase;
			}
			
			#content_document .headnotesContainer .headnote {
				margin-left: 24px;
			}
			
			#content_document .headnotesContainer .headnote .headnoteSlug {
				margin-top: 12px;
				font-size: 16px;
				font-weight: bold;
			}
			
			#content_document .headnotesContainer .headnote .headnoteDescriptor {
				margin-top: 12px;
				font-weight: bold;
			}
			
			#content_document .headnotesContainer .headnote .headnoteToggle .headnoteText {
				margin-bottom: 12px;
			}
		
</style>
<link href="/stylesheets/yui_calendar.css?1391022047" media="print,screen" rel="stylesheet" type="text/css" />
<link href="/stylesheets/docviewer_overrides.css?1391022005" media="print,screen" rel="stylesheet" type="text/css" />

<link href="/stylesheets/print.css?1391022029" media="print" rel="stylesheet" type="text/css" />
<link href='/images/favicon.ico' rel='shortcut icon'>
</head>
<body class='securities  document '>
<div class='container'>
<div id='page_loader'></div>
<div class='printHeader printOnly'>
<img src='/images/print_header.jpg'>
<div class='user'>
<span>
Prepared for: Susan Yeh
</span>
</div>
</div>
<div class='topBarHolder printHide'>
<div class='topBar'>
<ul class='topBarElements'>
<li class='skip'>
<a href="#primary_content" tabindex="1">Skip Navigation</a>
</li>
<li class='logout'>
<a href="/log_out.htm" id="logoutButton" onclick="generateExplicitLogoutEvent();">Logout</a>
</li>
<li id='help'>
<a href="/help" target="_blank">Help</a>

</li>
<li id='user'>
<a href="/settings">Susan Yeh</a>

</li>
<li class='withNotifications' id='client_matter'>
<div class='clientMatterDropDown'>
<div>Client Matter</div>
<div class='skinButton blueAlert' style='display:none'>
<span id='currentClientMatter'>

</span>
</div>
<span class='noneSelected' style=''>
&nbsp;(None Selected)
</span>
<div class='expandable'></div>
</div>
<div class='topNavDropdown' id='sub_client_matter'>
<ul>
<li style='display:none'>
<a class='remove_client_matter_menu_item' href='#' onclick='return true;' title='Remove Current Client Matter'>
Remove Current Client Matter
</a>
</li>
<li>
<a class='enter_client_matter_menu_item' href='#' onclick='return true;' title='Enter Client Matter'>
Enter Client Matter
</a>
</li>
</ul>
</div>

</li>
<li class='withNotifications' id='alerts'>
<a href="/alerts/inbox"><div id='unreadAlertsCount'>
Saved Searches & Alerts
</div>
</a>
</li>
<li class='withNotifications' id='downloads'>
<a href="/download/download_center"><div id='unreadDownloadsCount'>
<div>Downloads</div>
</div>
</a>
</li>
<li id='research_trail'>
<a href="/research_trail"><div>Research Trail</div>
</a>
</li>
<li id='workspaces'>
<a href="/workspaces"><div>Workspaces</div>

</a></li>
</ul>
</div>
</div>

<div class='topMenu textBkDark printHide' id='top_menu'>
<div class='contextHolder'>
<a href='/home'>
<h1 class='logo'></h1>
</a>
<div class='menuRow'>
<ul class='menuItems'>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_HOME' onclick="javascript:navigation_selectMenuItem('HOME');">
Home
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button active' id='nav_menu_button_search' onclick="javascript:navigation_selectMenuItem('search');">
Search & Browse
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_practice_areas' onclick="javascript:navigation_selectMenuItem('practice_areas');">
Practice Centers
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_LITIGATION' onclick="javascript:navigation_selectMenuItem('LITIGATION');">
Litigation & Dockets
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_transactional' onclick="javascript:navigation_selectMenuItem('transactional');">
Transactional Law
</a>
</li>
<li class='' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_LEG_REG' onclick="javascript:navigation_selectMenuItem('LEG_REG');">
Legislative & Regulatory
</a>
</li>
<li class='legalAnalysis' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_news' onclick="javascript:navigation_selectMenuItem('news');">
Legal Analysis & News
</a>
</li>
<li class='last' id='nav_menu_button'>
<a class='nav_menu_button ' id='nav_menu_button_market' onclick="javascript:navigation_selectMenuItem('market');">
Companies & Markets
</a>
</li>

</ul>
</div>
<form accept-charset="UTF-8" action="/autocomplete/jump" id="search_form" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div>
<input id='quicksearch_context' name='context_value' type='hidden' value='PRACTICE'>
<div class='searchBox' id='quick_search'>
<div class='inputContainer'>
<input autocomplete='off' id='quick_search_term' name='term' onkeydown='framework_handleTextInput(event,quick_search_term)' tabindex='2' type='text'>
<div class='searchButton' onmouseup='return framework_activateForm();' tabindex='3'></div>
<a href="/help/BLAWHelpSystem.htm#GO_Using_the_GO_BAR.htm" class="infoBtn" target="_blank" title="Using the &lt;GO&gt; Bar"></a>
<input id='quick_search_post' name='qs_type' type='hidden' value='general'>
<input id='quick_search_type' name='type' type='hidden' value='input_terms'>
<input id='quick_search_value' name='item_value' type='hidden'>
<input id='quick_search_origin' name='search_type' type='hidden' value='LAW'>
</div>
</div>
</form>


</div>
</div>

<div class='main clearfix'>
<div class='menuDrawer'>
<div class='interior'>
<div class='drawer_shade drawerShade clearfix'>
<div class='dropShadow'></div>
<div class='sub_menu subMenu' id='sub_menu_HOME'>
<table>
<tr>
<td class=''>
<ul>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_search'>
<div class='subTitles'>
<div class='subItem one '>
Search
</div>
<div class='subItem two '>
Specialized Searches
</div>
<div class='subItem one last'>
Browse
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class=''>
<ul>
<li class='last'>
<a class='clearfix' href='/legal_search'>
<div class='navLinkTitle'>
All Legal Content
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/company_search'>
<div class='navLinkTitle'>
Company Screener
</div>
</a>
</li>
<li>
<a class='clearfix' href='/opinion_search'>
<div class='navLinkTitle'>
Court Opinions
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dealmaker_document_search'>
<div class='navLinkTitle'>
DealMaker Documents
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dockets'>
<div class='navLinkTitle'>
Dockets
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dnds_search'>
<div class='navLinkTitle'>
Domain Name Decisions
</div>
</a>
</li>
<li>
<a class='clearfix' href='/edgar_search'>
<div class='navLinkTitle'>
EDGAR
</div>
</a>
</li>
<li>
<a class='clearfix' href='/clthreads/company-search-clc.php' target='_blank'>
<div class='navLinkTitle'>
EDGAR Comment Threads
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/leg_search'>
<div class='navLinkTitle'>
Legislative
</div>
</a>
</li>
<li>
<a class='clearfix' href='/news/advanced_search'>
<div class='navLinkTitle'>
News
</div>
</a>
</li>
<li>
<a class='clearfix' href='/patent_search'>
<div class='navLinkTitle'>
Patents
</div>
</a>
</li>
<li>
<a class='clearfix' href='/people_search'>
<div class='navLinkTitle'>
People
</div>
</a>
</li>
<li>
<a class='clearfix' href='/reg_search'>
<div class='navLinkTitle'>
Regulatory
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/no_action_search'>
<div class='navLinkTitle'>
SEC No-Action Letters
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/law_reports'>
<div class='navLinkTitle'>
BNA Law Reports
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.456024'>
<div class='navLinkTitle'>
BNA Manuals
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.456026'>
<div class='navLinkTitle'>
BNA Portfolios
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.102923'>
<div class='navLinkTitle'>
Books & Treatises
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_content_menu/105.293113'>
<div class='navLinkTitle'>
Federal Law
</div>
</a>
</li>
<li>
<a class='clearfix' href='/map_nav/laws_regs'>
<div class='navLinkTitle'>
State Law
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_practice_areas'>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/antitrust'>
<div class='navLinkTitle'>
Antitrust
</div>
</a>
</li>
<li>
<a class='clearfix' href='/banking_finance'>
<div class='navLinkTitle'>
Banking & Finance
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/bankruptcy'>
<div class='navLinkTitle'>
Bankruptcy
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/corporate_ma'>
<div class='navLinkTitle'>
Corporate/M&A
</div>
</a>
</li>
<li>
<a class='clearfix' href='/employee_benefits'>
<div class='navLinkTitle'>
Employee Benefits
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/health'>
<div class='navLinkTitle'>
Health
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/ip_law'>
<div class='navLinkTitle'>
Intellectual Property
</div>
</a>
</li>
<li>
<a class='clearfix' href='/labor_employment'>
<div class='navLinkTitle'>
Labor & Employment
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/securities'>
<div class='navLinkTitle'>
Securities
</div>
</a>
</li>
<li>
<a class='clearfix' href='/tax'>
<div class='navLinkTitle'>
Tax
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_LITIGATION'>
<div class='subTitles'>
<div class='subItem two '>
Litigation
</div>
<div class='subItem two last'>
Dockets
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/opinion_search'>
<div class='navLinkTitle'>
Search Court Opinions
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_menu/X7TO28O'>
<div class='navLinkTitle'>
BNA Outlines & Headnotes
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/nav_content_menu/105.103000'>
<div class='navLinkTitle'>
Federal Rules
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/general'>
<div class='navLinkTitle'>
Litigation Resources
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/dockets'>
<div class='navLinkTitle'>
Search Dockets
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dockets/breaking'>
<div class='navLinkTitle'>
Breaking Complaints
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/dockets/analytics'>
<div class='navLinkTitle'>
Docket Analytics
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/dockets/coverage'>
<div class='navLinkTitle'>
Docket Coverage
</div>
</a>
</li>
<li>
<a class='clearfix' href='/dockets/requests'>
<div class='navLinkTitle'>
Docket Requests
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/dockets/tracking'>
<div class='navLinkTitle'>
Docket Tracking
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_transactional'>
<div class='subTitles'>
<div class='subItem two '>
Search
</div>
<div class='subItem two last'>
Resources
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/edgar_search'>
<div class='navLinkTitle'>
EDGAR
</div>
</a>
</li>
<li>
<a class='clearfix' href='/clthreads/company-search-clc.php' target='_blank'>
<div class='navLinkTitle'>
EDGAR Comment Threads
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/example_and_saved_searches'>
<div class='navLinkTitle'>
Example Searches
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/dealmaker_document_search'>
<div class='navLinkTitle'>
DealMaker Documents
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/dealmaker_clause_search'>
<div class='navLinkTitle'>
DealMaker Clauses
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/deal_maker/current_awareness'>
<div class='navLinkTitle'>
Current Awareness
</div>
</a>
</li>
<li>
<a class='clearfix' href='/nav_menu/X7TS80O'>
<div class='navLinkTitle'>
Drafting Guides & Overviews
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/nav_menu/X7TVS0O'>
<div class='navLinkTitle'>
Transactional Legal Treatises
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/deal_maker/resources'>
<div class='navLinkTitle'>
Transactional Resources
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_LEG_REG'>
<div class='subTitles'>
<div class='subItem two '>
Legislative
</div>
<div class='subItem two last'>
Regulatory
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/leg_search'>
<div class='navLinkTitle'>
Search Legislative
</div>
</a>
</li>
<li>
<a class='clearfix' href='/leg_search/congressional_bill_search'>
<div class='navLinkTitle'>
Search Congressional Bills
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_browser/105.24221'>
<div class='navLinkTitle'>
U.S. Code
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/map_nav/laws_regs'>
<div class='navLinkTitle'>
State Legislative Materials
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/leg_news_analysis'>
<div class='navLinkTitle'>
Legislative Resources
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/reg_search'>
<div class='navLinkTitle'>
Search Regulatory
</div>
</a>
</li>
<li>
<a class='clearfix' href='/reg_search/federal_register_search'>
<div class='navLinkTitle'>
Search Federal Register
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_browser/105.24230'>
<div class='navLinkTitle'>
Code of Federal Regulations
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/map_nav/laws_regs'>
<div class='navLinkTitle'>
State Regulatory Materials
</div>
</a>
</li>
<li>
<a class='clearfix' href='/reg_updates'>
<div class='navLinkTitle'>
Monitor Regulators
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/reg_news_analysis'>
<div class='navLinkTitle'>
Regulatory Resources
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_news'>
<div class='subTitles'>
<div class='subItem two '>
Legal Analysis
</div>
<div class='subItem two last'>
News
</div>
<div class='clearfix'></div>
</div>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/law_reports'>
<div class='navLinkTitle'>
BNA Law Reports
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_content_menu/105.456024'>
<div class='navLinkTitle'>
BNA Manuals
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/nav_content_menu/105.456026'>
<div class='navLinkTitle'>
BNA Portfolios
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/nav_content_menu/105.102923'>
<div class='navLinkTitle'>
Books & Treatises
</div>
</a>
</li>
</ul>
</td>
<td class='subNavGutter'></td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/news/advanced_search'>
<div class='navLinkTitle'>
Search News
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/news'>
<div class='navLinkTitle'>
Legal News
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li>
<a class='clearfix' href='/news/topic'>
<div class='navLinkTitle'>
News by Topic
</div>
</a>
</li>
<li>
<a class='clearfix' href='/news/top_news'>
<div class='navLinkTitle'>
TOP News
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>
<div class='sub_menu subMenu' id='sub_menu_market'>
<table>
<tr>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/business_development'>
<div class='navLinkTitle'>
Business Development Center
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/edgar_search'>
<div class='navLinkTitle'>
Search EDGAR
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li>
<a class='clearfix' href='/company'>
<div class='navLinkTitle'>
Company Watchlist
</div>
</a>
</li>
<li class='last'>
<a class='clearfix' href='/company_search'>
<div class='navLinkTitle'>
Company Screener
</div>
</a>
</li>
</ul>
</td>
<td class='backgroundExtend'>
<ul>
<li class='last'>
<a class='clearfix' href='/report_writer'>
<div class='navLinkTitle'>
Company Report Writer
</div>
</a>
</li>
</ul>
</td>
<td class=''>
<ul>
<li class='last'>
<a class='clearfix' href='/market'>
<div class='navLinkTitle'>
Market News
</div>
</a>
</li>
</ul>
</td>
</tr>
</table>
</div>

</div>
</div>
<div class='bottomFlange'></div>
</div>
<div class='breadcrumbContainer printHide'>
<div class='breadHolder'>
<!-- .breadcrumb -->
<div class='breadcrumb' id='breadcrumb_0'>
Search & Browse
</div>

<div class='breadcrumbDivider'>
/
</div>
<!-- .breadcrumb -->
<div class='breadcrumb' id='breadcrumb_1'>
<a href='/conversion/resolve_search/9e80f4ac7146e23390fa86e1f038dd82'>
Court Opinions
</a>
</div>

<div class='breadcrumbDivider'>
/
</div>
<!-- .breadcrumb -->
<div class='breadcrumb' id='breadcrumb_2'>
<a href='/opinion_search/results/9e80f4ac7146e23390fa86e1f038dd82'>
Search Results
</a>
</div>

<div class='breadcrumbDivider'>
/
</div>
</div>
</div>

</div>
<div class='page clearfix'>
<div class='content' id='page_content'>
<div id='statusHolder'></div>
<a name='primary_content'></a>
<div class='document_search_links_container printHide'>
<div class='prev_search_result_container'>
<div class='attachmentPanelBackButton' onclick="document.location = $('.prev_search_result_link a').attr('href')"></div>
<div class='prev_search_result_link'>
<a href="/s/opinion/9e80f4ac7146e23390fa86e1f038dd82/document/X1I18OI003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" class="{}" data-doc-id="X1I18OI003">Previous Result: <span>Fox v. Mortgage Electronic Registration ...</span></a>
<div class='clearfix'></div>
</div>
</div>
<div class='next_search_result_container'>
<div class='next_search_result_link'>
<a href="/s/opinion/9e80f4ac7146e23390fa86e1f038dd82/document/X1I18PC003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" class="{}" data-doc-id="X1I18PC003">Next Result: <span>Calabrese v. LeGrand, No. 2:12-CV-00800-...</span></a>
<div class='clearfix'></div>
</div>
<div class='attachmentPanelForwardButton' onclick="document.location = $('.next_search_result_link a').attr('href')"></div>
</div>
<div class='clearfix'></div>
</div>
<div class='clearfix'></div>

<div class='breadCrumbTitleRow clearfix eight grid'>
<div class="icon citation positive" title="Positive"></div>
<div class='title left' title='Kuhn v. Wyeth, Inc., 686 F.3d 618 (8th Cir. 2012), Court Opinion'>
Kuhn v. Wyeth, Inc., 686 F.3d 618 (8th Cir. 2012), Court Opinion
</div>
</div>

<div class='metadata' style='display: none'>
<div class='documentTitle'>Kuhn v. Wyeth, Inc., 686 F.3d 618 (8th Cir. 2012), Court Opinion</div>
<div class='docId'>X1I1772003</div>
<div class='docType'>OPINIONS</div>
<div class='case_name'>Kuhn v. Wyeth, Inc.</div>
<div class='displayCitation'>2012 BL 186244</div>
<div class='displayCitation'>686 F.3d 618</div>
<div class='displayCitation'>bna a0d3w4e6j3</div>
<div class='displayCitation'>wkf8case:26234481</div>
</div>

<div class='search_outline_node_popup' style='display:none'>
<form accept-charset="UTF-8" action="/document/class_outline_search" id="search_document_node_form" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div>
<div class='clearfix popupTitle'>
<div class='close' onclick='closePopup()'></div>
<h2>Search</h2>
</div>
<p class='searchOver'>
Search over:
<span class='search_target_node'></span>
<input class="search_source_id" id="source_id" name="source_id" type="hidden" />
<input class="search_node_id" id="search_node_id" name="search_node_id" type="hidden" />
<input class="search_service_code" id="search_service_code" name="search_service_code" type="hidden" />
<input class="search_division" id="search_division" name="search_division" type="hidden" />
<input autocomplete="off" class="search_node_text" id="search_term" name="search_term" type="text" />
</p>
<div class='clearfix'></div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right print' onclick='this.form.submit();'>
<span>
Search
</span>
</button>
<button class='bootstrap skinButton popup cancel right' onclick='closePopup();' type='button'>
<span>
Cancel
</span>
</button>
</div>
</form>

</div>
<div id='no_matching_keywords_popup' style='display:none'>
<div class='popupTitle clearfix'>
<div class='close' onclick='closePopup()'></div>
<h2>No Matches Found</h2>
</div>
<p>
Search term(s) not found.
</p>
<div class='popUpActions'>
<button class='bootstrap skinButton popup cancel right' onclick='closePopup();' type='button'>
<span>
Close
</span>
</button>
</div>
</div>
<div id='copyWithCitationPopupContents' style='display:none'>
<div class='popupTitle clearfix'>
<div class='close' onclick='closePopup()'></div>
<h2>Copy with Citation</h2>
</div>
<p>
Copy the text below to paste into your document.
</p>
<div class='clearfix'>
<div class='copyWithCitationScrollBox'>
<div class='copyWithCitationArea left'>
<div class='copyWithCitationText'></div>
<div class='copyWithCitationDocumentTitle'></div>
</div>
<div class='ie9compat left'>
<img alt="" src="/images/transparency.png?1296705112" width="1" />
</div>
</div>
</div>
<div class='copyWithCitationCheckBoxHolder'>
<input checked="checked" class="linkCitation" id="link_citation" name="link_citation" onclick="updateCopyWithCitationLinks()" type="checkbox" value="true" />
Link citations to Bloomberg Law
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right' onclick='closePopup();' type='button'>
<span>
Close
</span>
</button>
</div>
</div>

<script type='text/javascript'>
  //<![CDATA[
    $('#page_content').addClass("invisible");
  //]]>
</script>
<input id="doc_id" name="doc_id" type="hidden" value="X1I1772003" />
<input id="hidden_document_title" name="hidden_document_title" type="hidden" value="Kuhn v. Wyeth, Inc., 686 F.3d 618 (8th Cir. 2012), Court Opinion" />
<input id="hidden_case_name" name="hidden_case_name" type="hidden" value="Kuhn v. Wyeth, Inc." />
<input id="hidden_case_docket" name="hidden_case_docket" type="hidden" />
<div class='toolHolder'>
<form accept-charset="UTF-8" action="" id="downloadPopupLinkForm" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div><input id="pde_location_type" name="pde_location_type" type="hidden" value="DOCUMENT" /><input id="full_doc_path" name="full_doc_path" type="hidden" value="/s/opinion/9e80f4ac7146e23390fa86e1f038dd82/document/X1I1772003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" /><input id="document_type" name="document_type" type="hidden" value="OPINIONS" /><input id="doc_id" name="doc_id" type="hidden" value="X1I1772003&amp;search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" /><input id="artifact_id" name="artifact_id" type="hidden" value="X1I1772003" /><input id="title" name="title" type="hidden" value="Kuhn v. Wyeth, Inc., 686 F.3d 618 (8th Cir. 2012), Court Opinion" /><input id="search32" name="search32" type="hidden" value="DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" /><input id="citation_analysis" name="citation_analysis" type="hidden" value="POSITIVE" /><input id="context_resource_id" name="context_resource_id" type="hidden" value="9e80f4ac7146e23390fa86e1f038dd82" /><input id="has_sidebar_info" name="has_sidebar_info" type="hidden" value="true" /><input id="tab_types_" name="tab_types[]" type="hidden" value="TAB_OPINION" /><input id="has_notepad" name="has_notepad" type="hidden" value="true" /><input id="notepad_id" name="notepad_id" type="hidden" value="X1I1772003" /><input id="has_headnotes" name="has_headnotes" type="hidden" value="false" /><input id="preselect_option" name="preselect_option" type="hidden" value="DOCUMENT" /></form>

<ul class='tools printHide'>
<li>
<a href="#" onclick="javascript:quickPrintLink(); return false;">Quick Print</a>

</li>
<li>
<a href="#" onclick="javascript:createFormPopupFromForm('download','downloadPopupLinkForm'); return false;">Print/Download</a>
</li>
<li>
<a href="#" onclick="javascript:createFormPopupFromForm('email','downloadPopupLinkForm'); return false;">Email</a>
</li>
<li>
<a href="#" onclick="javascript:addPopupForm('add_to_workspace','?resource_path=%2Fs%2Fopinion%2F%39e%38%30f%34ac%37%31%34%36e%32%33%33%39%30fa%38%36e%31f%30%33%38dd%38%32%2Fdocument%2FX%31I%31%37%37%32%30%30%33%3Fsearch%33%32%3DDPNLUQBDE%31FN%30Q%33IC%35PMASPT%36%34TJMSRPDPNMSUBDECUJ%32&amp;document_type=OPINIONS', null); return false;">+ Workspace</a>
</li>
<li>
<a onclick='javascript:PDETray_default.addSelection();'>
+ Queue
</a>
</li>
<li class='last'></li>
</ul>
</div>

<div class='bootstrap printHide tabs'>
<a class='borderTab activeTab' id='tab_DOCUMENT'>
Document
</a>

<a href="/s/opinion/9e80f4ac7146e23390fa86e1f038dd82/bcite/X1I1772003/history" class="borderTab inactiveTab" id="tab_HISTORY" onclick="docTabSpinner()">Direct History</a>

<a href="/s/opinion/9e80f4ac7146e23390fa86e1f038dd82/bcite/X1I1772003/analysis" class="borderTab inactiveTab" id="tab_ANALYSIS" onclick="docTabSpinner()">Case Analysis</a>

<a href="/s/opinion/9e80f4ac7146e23390fa86e1f038dd82/bcite/X1I1772003/toa" class="borderTab inactiveTab" id="tab_TOA" onclick="docTabSpinner()">Table of Authorities</a>

<a href="/s/opinion/9e80f4ac7146e23390fa86e1f038dd82/related_content/X1I1772003?search32=DPNLUQBDE1FN0Q3IC5PMASPT64TJMSRPDPNMSUBDECUJ2" class="borderTab inactiveTab" id="tab_CITING_DOCS" onclick="docTabSpinner()">Citing Documents</a>

<div class='showHide printHide'>
<div class='showHideSidebarArrow'>
<a class='bliderText' id='bliderLink'>
<span id='bliderText'>
Hide General Info & Notepad
</span>
<span id='notepadCountLabel'></span>
</a>
</div>
</div>

</div>

<!-- document -->
<script type='text/javascript'>
  //<![CDATA[
    var fluid_layout=false;
  //]]>
</script>

<!-- %table.markupContainment -->
<!-- %tbody -->
<!-- %tr -->
<!-- %td#markup_holder{:valign=>"top", :align=>"left"} -->
<div class='docHolder legal hasSearchTerms ' id='doc_holder'>
<div class='documentContent ' id='content_document'>


<script type="text/javascript">
					function Blaw__Citator()
					{
						window.location="bloomberg:bcite_url_prefix=/rest/documents/1719302946819";
					}
				</script><script type="text/javascript">
      var BLAW_TOTAL_KEYWORD = 0;
      var BLAW_CURRENT_KEYWORD = -1;
      var BLAW_LAST_COLOR = "yellow";
      var BLAW_ANCHOR_NAME = "blawkeyword";
      var BLAW_BASE_URL = document.location.href;

      function Blaw__changeCurElem(lastAnchor, newAnchor)
      {
        var baseUrl = Blaw__getBaseURL(document.location.href);
        document.location.href = baseUrl + "#" + newAnchor;
        var elem = document.getElementById(lastAnchor)[0];
        if (elem) {
          elem.style.backgroundColor = BLAW_LAST_COLOR;
        }
        elem = document.getElementById(newAnchor)[0];
        if (elem) {
          BLAW_LAST_COLOR = elem.style.backgroundColor;
          elem.style.backgroundColor = "orange";
        }
      }

      function Blaw__findNextKeyWord()
      {
        var looped = false;
        var lastAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        if (++BLAW_CURRENT_KEYWORD >= BLAW_TOTAL_KEYWORD) {
          BLAW_CURRENT_KEYWORD = 0;
        }

        // if index does not exist on page continue to inc until one does
        while(document.getElementById(BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD).length == 0 && BLAW_CURRENT_KEYWORD < BLAW_TOTAL_KEYWORD) {
            ++BLAW_CURRENT_KEYWORD;
            // wrap around search, once only
            if (BLAW_CURRENT_KEYWORD >= BLAW_TOTAL_KEYWORD && !looped) {
              BLAW_CURRENT_KEYWORD = 0;
              looped = true;
            }
        }
        var newAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        Blaw__changeCurElem(lastAnchor, newAnchor);
      }

      function Blaw__findPrevKeyWord()
      {
        var looped = false;
        var lastAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        if (--BLAW_CURRENT_KEYWORD < 0) {
          BLAW_CURRENT_KEYWORD = BLAW_TOTAL_KEYWORD - 1;
          looped = true;
        }

        // if index does not exist on page continue to decr until one does
        while(document.getElementById(BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD).length == 0 && BLAW_CURRENT_KEYWORD >= 0) {
          --BLAW_CURRENT_KEYWORD;
          // wrap around search, once only
          if (BLAW_CURRENT_KEYWORD < 0 && !looped) {
            BLAW_CURRENT_KEYWORD = BLAW_TOTAL_KEYWORD - 1;
            looped = true;
          }
        }
        var newAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        Blaw__changeCurElem(lastAnchor, newAnchor);
      }

      function Blaw__findNextFrom(indx)
      {
        var lastAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        BLAW_CURRENT_KEYWORD = indx;
        ++BLAW_CURRENT_KEYWORD;
        if (BLAW_CURRENT_KEYWORD >= BLAW_TOTAL_KEYWORD) {
          BLAW_CURRENT_KEYWORD = 0;
        }
        var newAnchor = BLAW_ANCHOR_NAME + BLAW_CURRENT_KEYWORD;
        Blaw__changeCurElem(lastAnchor, newAnchor);
      }

      function Blaw__getBaseURL(url)
      {
        var reg = new RegExp("(.+)#.+$");
        var ar = reg.exec(url);
        if (ar != null) {
          return ar[1];
        } else {
          return url;
        }
      }


    </script><div xmlns:fo="http://www.w3.org/1999/XSL/Format" class="metadata" style="display: none">
<div class="pagination_series_list">PrimaryFederalReporter,Bloomberg,</div>
<div class="citation-group">
<div class="cite" data-cite-type="PrimaryFederalReporter">686 F.3d 618</div>
<div class="cite" data-cite-type="DocketNumber">Nos. 11-1809, 11-1815.</div>
<div class="cite" data-cite-type="Bloomberg">2012 BL 186244</div>
</div>
</div>
<div align="left" class="tableofcontents">
<br CLEAR="right"><div class="page_text" style="float:right">
<b>Pagination</b><table class="page_legend" cellspacing="0">
<tr>
<td width="25%" align="left" valign="top">*</td>
<td width="50%" align="left" valign="top">F.3d </td>
</tr>
<tr>
<td width="25%" align="left" valign="top">**</td>
<td width="50%" align="left" valign="top">BL</td>
</tr>
</table>
</div>
<br>
</div>
<table><tbody><tr><td>&nbsp;</td></tr></tbody></table>
<p><center>
United States Court of Appeals, Eighth Circuit.
</center></p>
<hr align="center" width="65%">
<p><center>
Pamela KUHN, Appellant, v. WYETH, INC., formerly known as American Home
Products; Wyeth Pharmaceuticals, Inc., formerly known as Wyeth-Ayerst
Pharmaceuticals, Inc., Appellees.
</center></p>
<p><center>
Arkansas Trial Lawyers Association, Amicus Curiae. Shirley Davidson,
Appellant, v. Wyeth; Wyeth Pharmaceuticals, Inc., Appellees.
</center></p>
<hr align="center" width="65%">
<p><center>
Nos. 11-1809, 11-1815.
</center></p>
<p><center>
Submitted: January 10, 2012.
</center></p>
<p><center>
Filed: July 26, 2012.
</center></p>
<div id="para2" printdualcolumn="true"><p>
Appeal from the United States District Court for the Western District of
Arkansas, Billy Roy Wilson, J.
<span CLASS="page_no" data-cite="686 f 3d 619" data-cite-type="PrimaryFederalReporter" data-cite-pageno="619" data-primary-citation="686 F.3d 618">[*619]</span> 
[EDITORS' NOTE: THIS PAGE CONTAINED HEADNOTES AND HEADNOTES ARE NOT AN
OFFICIAL PRODUCT OF THE COURT, THEREFORE THEY ARE NOT DISPLAYED.]
</p></div>
<span CLASS="page_no" data-cite="686 f 3d 620" data-cite-type="PrimaryFederalReporter" data-cite-pageno="620" data-primary-citation="686 F.3d 618">[*620]</span> <div id="para2" printdualcolumn="true"><p>
Erik Brett Walker, argued, Austin, TX, Breean Walas, on the brief, North
Little Rock, AR, for appellants.
</p></div>
<div id="para2" printdualcolumn="true"><p>
Loren Howard Brown, argued, Christopher G. Campbell, on the brief, New York,
NY, for appellees.
</p></div>
<div id="para2" printdualcolumn="true"><p>
Brian Gene Brooks, on the brief, Greenbrier, AR, for amicus curiae.
</p></div>
<div id="para2" printdualcolumn="true"><p>
Before WOLLMAN, LOKEN and GRUENDER, Circuit Judges.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
WOLLMAN, Circuit Judge.
</p></div>
<div id="contentOpinion" printdualcolumn="true">
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Pamela Kuhn and Shirley Davidson were prescribed Prempro, a hormone
therapy drug comprised of estrogen and progestin and manufactured by
Wyeth.<a HREF="#fn100" name="fnref_fn100">[fn1]</a> Kuhn took Prempro for three years and twenty-eight days;
Davidson took it for one year and nine months. Both women developed breast
cancer and filed separate lawsuits against Wyeth in the Western District of
Arkansas. The complaints alleged, among other things, that the use of
Prempro increased the risk of breast cancer and that Wyeth failed to
adequately warn of the drug's adverse effects. Both cases were transferred
to the Multidistrict Litigation proceedings in the Eastern District of
Arkansas, where Wyeth moved to preclude any expert testimony that Prempro
use increases breast cancer risk when taken for three years or less.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  On behalf of Kuhn and Davidson (collectively, Plaintiffs), Donald F.
Austin, M.D., opined that short-term use of Prempro increases the risk of
breast cancer. The magistrate judge to whom the evidentiary matter was
referred concluded that Dr. Austin's opinion was not sufficiently reliable
to meet the admissibility standard set forth in <i>Daubert v. Merrell Dow</i>
<i>Pharmaceuticals, Inc.</i>, <a href="/s/opinion/9e80f4ac7146e23390fa86e1f038dd82/document/X2N776?jcsearch=509%20us%20579&amp;summary=yes#jcite">509 U.S. 579</a>, <a href="/s/opinion/9e80f4ac7146e23390fa86e1f038dd82/document/1?citation=113%20supreme%20court%202786&amp;summary=yes#jcite">113 S.Ct. 2786</a>, <a href="/s/opinion/9e80f4ac7146e23390fa86e1f038dd82/document/X2N776?jcsearch=125%20l%20ed%202d%20469&amp;summary=yes#jcite">125 L.Ed.2d 469</a> (1993),
and thus granted Wyeth's motion. Thereafter, the district court overruled
Plaintiffs' objections to the <i>Daubert</i> order, granted Wyeth's motion for
summary judgment, entered judgment dismissing the two cases, and denied
Plaintiffs' post-trial motions.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Kuhn and Davidson appeal. They argue that the magistrate judge abused his
discretion in granting Wyeth's motion to preclude
<span CLASS="page_no" data-cite="686 f 3d 621" data-cite-type="PrimaryFederalReporter" data-cite-pageno="621" data-primary-citation="686 F.3d 618">[*621]</span> 
expert testimony and that summary judgment based on the preclusion of expert
testimony was inappropriate. Kuhn also argues that her case did not qualify
as a short-term use case because she had taken Prempro for more than three
years. We conclude that the magistrate judge abused his discretion in
precluding Dr. Austin's expert testimony, and thus we reverse and remand for
further proceedings.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  I. Background
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  A. General Background
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Prempro is a combination hormone therapy composed of conjugated equine
<span CLASS="page_no" data-cite="2012 bl 186244 p 2" data-cite-type="Bloomberg" data-cite-pageno="2" data-primary-citation="">[**2]</span> estrogen and medroxyprogesterone acetate.<a HREF="#fn200" name="fnref_fn200">[fn2]</a> It is used to treat symptoms
of menopause, including vasomotor symptoms and vaginal atrophy. <i>See</i>
<i>Physician's Desk Reference</i> 3394 (65th ed. 2011).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In the 1990s, the National Institutes of Health began studying the effects
of hormone therapy drugs as part of its Women's Health Initiative
(WHI).<a HREF="#fn300" name="fnref_fn300">[fn3]</a> More than 160,000 postmenopausal women between fifty and
seventy-nine years of age enrolled in a set of clinical trials, including a
randomized controlled trial of combined estrogen and progestin (the WHI
study). The WHI study included 16,608 participants and assessed the risks
and benefits of taking Prempro daily, compared to taking a placebo, in the
prevention of certain chronic diseases. <i>Id.</i> at 3400-01. The study was
brought to a premature conclusion, however, after the increased risk of
breast cancer and certain cardiovascular events exceeded the study's
specified benefits. <i></i><cite>Id. at 3401</cite>. As reported in the Journal of the American
Medical Association, the WHI study found that the use of estrogen plus
progestin increases the risk of breast cancer. Jacques E. Rossouw et al.,
<i>Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal</i>
<i>Women</i>, 288 JAMA 321 (2002).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Following the publication of the WHI study results, thousands of women
filed lawsuits against Wyeth and other hormone therapy drug manufacturers,
alleging that hormone therapy increased the risk of breast cancer and that
the companies had failed to warn of that risk. In 2003, the federal lawsuits
were consolidated in the Eastern District of Arkansas.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  B. Procedural Posture of Kuhn's and Davidson's Lawsuits
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In late October 2010, the district court selected Kuhn's and Davidson's
cases to go to trial. Earlier that month, the district court had directed
the parties to provide "a list of all `short-term use' Plaintiffs who filed
cases in either the Eastern District or Western District of Arkansas." Kuhn
App. 49. The district court selected Davidson from the list of plaintiffs
who had used Prempro for three years or less. The court also selected Kuhn,
who had
<span CLASS="page_no" data-cite="686 f 3d 622" data-cite-type="PrimaryFederalReporter" data-cite-pageno="622" data-primary-citation="686 F.3d 618">[*622]</span> 
taken Prempro for slightly more than three years and thus was not listed as
a "short-term use" plaintiff.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  On October 29, 2010, Wyeth advised the court that a short-term use case
was proceeding to trial in the District of Puerto Rico and that it planned
to file a <i>Daubert</i> challenge to the general causation opinions of the
plaintiffs experts. Because Wyeth would file similar challenges in both
Puerto Rico and Arkansas, Wyeth suggested that the two courts hear together
the <i>Daubert</i> challenge. The courts agreed, and a joint hearing was scheduled
for November 29, 2010, in Puerto Rico.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Prior to the hearing, Wyeth filed its motion to preclude expert
testimony.<a HREF="#fn400" name="fnref_fn400">[fn4]</a> Wyeth argued that there existed no reliable scientific basis
for Plaintiffs' experts to conclude that taking Prempro for less than three
years increases a woman's risk of developing breast cancer. Wyeth relied on
the WHI study's report that women who took Prempro for three years or less
had fewer incidents of breast cancer than <span CLASS="page_no" data-cite="2012 bl 186244 p 3" data-cite-type="Bloomberg" data-cite-pageno="3" data-primary-citation="">[**3]</span> those who took the placebo. It
argued that the medical and scientific communities had accepted the WHI
study as definitive and that the studies that Plaintiffs would rely upon
were methodologically flawed. Moreover, Wyeth cited evidence that the
experts Plaintiffs likely would call upon had admitted that Prempro does not
increase the risk of breast cancer when taken daily for three years or less.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In opposition, Plaintiffs set forth their position that estrogen plus
progestin (E + P) is a "growth promoting agent" that causes
cancer-susceptible cells to become cancerous. Kuhn App. 168. According to
Plaintiffs, the promotion effect can be seen in a matter of months. Hormone
therapy plaintiffs typically have relied on the WHI study to show that use
of Prempro causes an increased risk of breast cancer, but Kuhn and Davidson
argued that the study was not powerful<a HREF="#fn500" name="fnref_fn500">[fn5]</a> enough to detect whether
short-term use of Prempro caused an increased risk. Moreover, Plaintiffs
argued that the WHI study failed to account for gap time<a HREF="#fn600" name="fnref_fn600">[fn6]</a> and that
subsequent analysis of the study showed an increased risk of breast cancer
after two years of Prempro use. Plaintiffs cited a number of observational
studies that found an increased risk of breast cancer from E + P use of
three years or less.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  In its reply, Wyeth argued that Plaintiffs' evidence failed to establish a
reliable basis for concluding that short-term use of Prempro increases the
risk of breast cancer. Wyeth argued that Plaintiffs' criticisms of the WHI
study's findings were misguided, particularly because hormone therapy
litigation experts had relied so heavily on the study in the past and be
<span CLASS="page_no" data-cite="686 f 3d 623" data-cite-type="PrimaryFederalReporter" data-cite-pageno="623" data-primary-citation="686 F.3d 618">[*623]</span> 
cause the WHI study was a randomized control study, the "gold standard" of
epidemiological studies. Wyeth accused Plaintiffs of "cherry picking" from
the relevant observational studies, relying upon the ones that showed an
increased risk of breast cancer rather than the great weight of the studies
that showed no increased risk. Moreover, Wyeth argued that the observational
studies cited by Plaintiffs were inapplicable because they evaluated hormone
therapy formulations other than Prempro and failed to reliably assess
participants' duration of use. Wyeth also rebutted the promotion theory,
noting that even experts for hormone therapy litigation plaintiffs regarded
the theory as insufficient to establish causation.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  C. Dr. Austin's Opinion
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The day before the evidentiary hearing in Puerto Rico, Plaintiffs filed
the declaration of Dr. Austin, who opined that "E + P can, and often does
cause clinically detectable breast cancer in short-term durations including
a matter of months." Kuhn App. 3905. Dr. Austin set forth in his declaration
his standards for reviewing observational studies, including that he would
not rely on "underpowered" studies, which he defined as studies that were
not likely to identify an association or an effect, if one existed.<a HREF="#fn700" name="fnref_fn700">[fn7]</a> The
declaration also listed the following studies as useful in determining
whether a short-term risk existed: The Million Women Study, the <span CLASS="page_no" data-cite="2012 bl 186244 p 4" data-cite-type="Bloomberg" data-cite-pageno="4" data-primary-citation="">[**4]</span> French
Teachers Study (Fournier), the Li (2000) study, and the Saxena (2010) study.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Dr. Austin also opined that the WHI study's estimate of short-term risk
was "quite poor" due to shortcomings "that diminish the estimate of the
effect of short-term exposure." Kuhn App. 3902. He explained that the WHI
study participants were more than ten years past the onset of menopause,
meaning that they were much older than the women who typically start hormone
therapy. Moreover, the study tended to exclude women who were experiencing
moderate hot flashes. According to Dr. Austin, those women were more likely
to be estrogen deficient and more likely to be susceptible to the
carcinogenic effects of E + P. Dr. Austin also explained that the WHI
study's analysis necessarily underestimates the relative risk because
approximately forty percent of the participants dropped out of the study and
about eleven percent of the placebo group began taking E + P.<a HREF="#fn800" name="fnref_fn800">[fn8]</a> The
study's first report was thus flawed, Dr. Austin opined, because "women were
counted as E + P users who actually were not and vice versa." <i><cite>Id</cite>.</i> Dr. Austin
also listed other shortcomings that led the WHI study to underestimate
short-term risk, including that E + P makes breast cancer detection more
difficult and that the study included hormone-negative tumors in its
results.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  D. <i>Daubert</i> Hearings and Order Excluding Dr. Austin's Expert Opinion
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Given that Dr. Austin's declaration was filed on November 28, 2010, it was
not
<span CLASS="page_no" data-cite="686 f 3d 624" data-cite-type="PrimaryFederalReporter" data-cite-pageno="624" data-primary-citation="686 F.3d 618">[*624]</span> 
fully considered at the November 29, 2010, hearing in Puerto Rico. Because
no witnesses were called to testify, the hearing was limited to counsels'
arguments.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Shortly after the hearing, the district court asked Plaintiffs and Wyeth
to address the WHI study's finding that breast cancer incidents were lower
among the participants taking Prempro than those who were taking the placebo
during the first three years. Specifically, the court asked, "With respect
to short term use, please give me a short, pointed, pithy brief explaining
what evidence of your's meets the WHI findings on this point." Kuhn App.
3912. Plaintiffs reiterated the arguments they had made in opposition to
Wyeth's motion to preclude, including that the WHI study was not powerful
enough to detect a short-term risk, that it was not designed to do so, and
that other studies established a short-term effect. After reviewing the
parties' submissions, the district court ordered a second <i>Daubert</i> hearing
and called for live testimony from the parties' experts.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  On January 12, 2011, the magistrate judge held a lengthy <i>Daubert</i> hearing.
Dr. Austin and Wyeth's expert, Kurt Barn-hart, M.D., testified, fielding
questions from the attorneys and the court. During the hearing, Dr. Austin
conceded that the Li (2000) and Saxena (2010) studies should not have been
included in his expert report. Dr. Austin thus based his opinion that
short-term use of Prempro causes breast cancer on the Million Women Study,
the Fournier study, and the American Cancer Society Study (Calle
study).<a HREF="#fn900" name="fnref_fn900">[fn9]</a>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The magistrate judge issued an order the following week, granting Wyeth's
motion to preclude <span CLASS="page_no" data-cite="2012 bl 186244 p 5" data-cite-type="Bloomberg" data-cite-pageno="5" data-primary-citation="">[**5]</span> expert testimony.<a HREF="#fn1000" name="fnref_fn1000">[fn10]</a> The order stated, "The issue
before the Court is whether Dr. Austin, an epidemiologist and Plaintiffs'
general causation expert, can testify reliably that short-term use of
Prempro increases the risk of breast cancer." Order of January 19, 2011, at
1 (footnote omitted). The magistrate judge ultimately excluded the expert
evidence because it found that Dr. Austin failed to discredit the WHI
study's results and failed to base his opinion on epidemiological studies
that "reliably supporte[d] his position." <i></i><cite>Id. at 21</cite>.<a HREF="#fn1100" name="fnref_fn1100">[fn11]</a> The district
court denied Plaintiffs' objections to the order and their motion to
reconsider and later granted Wyeth's motion for summary judgment.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  II. Discussion
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  A. Expert Evidence
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  We review the decision to exclude expert evidence for an abuse of
discretion. <i>Gen. Elec. Co. v. Joiner</i>, <a href="/s/opinion/9e80f4ac7146e23390fa86e1f038dd82/document/X5CCVA?jcsearch=522%20us%20136&amp;summary=yes#jcite">522 U.S. 136</a>, <a href="/s/opinion/9e80f4ac7146e23390fa86e1f038dd82/document/X5CCVA?jcsearch=522%20us%20136&amp;summary=yes#jcite">143</a>, <a href="/s/opinion/9e80f4ac7146e23390fa86e1f038dd82/document/1?citation=118%20supreme%20court%20512&amp;summary=yes#jcite">118 S.Ct. 512</a>,
<a href="/s/opinion/9e80f4ac7146e23390fa86e1f038dd82/document/X5CCVA?jcsearch=139%20l%20ed%202d%20508&amp;summary=yes#jcite">139 L.Ed.2d 508</a> (1997);
<span CLASS="page_no" data-cite="686 f 3d 625" data-cite-type="PrimaryFederalReporter" data-cite-pageno="625" data-primary-citation="686 F.3d 618">[*625]</span> 
<i>Junk v. Terminix Int'l Co.</i>, <a href="/s/opinion/9e80f4ac7146e23390fa86e1f038dd82/document/X1EMNS8003?jcsearch=628%20f%203d%20439&amp;summary=yes#jcite">628 F.3d 439</a>, <a href="/s/opinion/9e80f4ac7146e23390fa86e1f038dd82/document/X1EMNS8003?jcsearch=628%20f%203d%20439&amp;summary=yes#jcite">447</a> (8th Cir.2010). The opinion of
a qualified expert witness is admissible if (1) it is based on sufficient
facts or data, (2) it is the product of reliable principles and methods, and
(3) the expert has reliably applied the principles and methods to the facts
of the case. Fed.R.Evid. <a href="/s/opinion/9e80f4ac7146e23390fa86e1f038dd82/document/X135KMG003?jcsearch=Fed.%20R.%20Evid.%20702&amp;summary=yes#jcite">702</a>. The expert's scientific, technical, or
specialized knowledge must also "assist the trier of fact to understand the
evidence or determine a fact in issue." <i><a href="/s/opinion/9e80f4ac7146e23390fa86e1f038dd82/document/X135KMG003?jcsearch=Fed.%20R.%20Evid.%20702&amp;summary=yes#jcite">Id</a>.</i> The district court is thus
vested with a gatekeeping function, ensuring that "any and all scientific
testimony or evidence admitted is not only relevant, but reliable." <i>Daubert</i>,
<a href="/s/opinion/9e80f4ac7146e23390fa86e1f038dd82/document/X2N776?jcsearch=509%20us%20579&amp;summary=yes#jcite">509 U.S. at 589</a>, <a href="/s/opinion/9e80f4ac7146e23390fa86e1f038dd82/document/1?citation=113%20supreme%20court%202786&amp;summary=yes#jcite">113 S.Ct. 2786</a>. The function also serves "to make certain
that an expert, whether basing testimony upon professional studies or
personal experience, employs in the courtroom the same level of intellectual
rigor that characterizes the practice of an expert in the relevant field."
<i>Kumho Tire Co., Ltd. v. Carmichael</i>, <a href="/s/opinion/9e80f4ac7146e23390fa86e1f038dd82/document/X2N7BT?jcsearch=526%20us%20137&amp;summary=yes#jcite">526 U.S. 137</a>, <a href="/s/opinion/9e80f4ac7146e23390fa86e1f038dd82/document/X2N7BT?jcsearch=526%20us%20137&amp;summary=yes#jcite">152</a>, <a href="/s/opinion/9e80f4ac7146e23390fa86e1f038dd82/document/1?citation=119%20supreme%20court%201167&amp;summary=yes#jcite">119 S.Ct. 1167</a>,
<a href="/s/opinion/9e80f4ac7146e23390fa86e1f038dd82/document/X2N7BT?jcsearch=143%20l%20ed%202d%20238&amp;summary=yes#jcite">143 L.Ed.2d 238</a> (1999).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  "[T]he requirement that an expert's testimony pertain to `scientific
knowledge' establishes a standard of evidentiary reliability." <i>Daubert</i>,
<a href="/s/opinion/9e80f4ac7146e23390fa86e1f038dd82/document/X2N776?jcsearch=509%20us%20579&amp;summary=yes#jcite">509 U.S. at 590</a>, <a href="/s/opinion/9e80f4ac7146e23390fa86e1f038dd82/document/1?citation=113%20supreme%20court%202786&amp;summary=yes#jcite">113 S.Ct. 2786</a>. The Supreme Court explained that
evidentiary reliability means trustworthiness. <i></i><a href="/s/opinion/9e80f4ac7146e23390fa86e1f038dd82/document/X2N776?jcsearch=509%20U.S.%20579&amp;summary=yes#jcite">Id. at 591</a> n. 9,
<a href="/s/opinion/9e80f4ac7146e23390fa86e1f038dd82/document/1?citation=113%20supreme%20court%202786&amp;summary=yes#jcite">113 S.Ct. 2786</a>. "Proposed testimony must be supported by appropriate
validation &mdash; <i>i.e.</i>, `good grounds,' based on what is known." <i></i><a href="/s/opinion/9e80f4ac7146e23390fa86e1f038dd82/document/X2N776?jcsearch=509%20U.S.%20579&amp;summary=yes#jcite">Id. at 590</a>,
<a href="/s/opinion/9e80f4ac7146e23390fa86e1f038dd82/document/1?citation=113%20supreme%20court%202786&amp;summary=yes#jcite">113 S.Ct. 2786</a>. The standard for judging the evidentiary reliability of
expert evidence is "lower than the merits standard of correctness." <i>In re</i>
<i>Paoli R.R. Yard PCB Litig.</i>, <a href="/s/opinion/9e80f4ac7146e23390fa86e1f038dd82/document/X3LRV6?jcsearch=35%20f%203d%20717&amp;summary=yes#jcite">35 F.3d 717</a>, <a href="/s/opinion/9e80f4ac7146e23390fa86e1f038dd82/document/X3LRV6?jcsearch=35%20f%203d%20717&amp;summary=yes#jcite">744</a> (3d Cir.1994). Proponents of
expert testimony need not demonstrate that the assessments of their experts
are correct, and trial courts are not empowered "to determine which of
several competing scientific theories has the best provenance." <i>Milward v.</i>
<i>Acuity Specialty Prods. Grp.</i>, <a href="/s/opinion/9e80f4ac7146e23390fa86e1f038dd82/document/X1F5DQ8003?jcsearch=639%20f%203d%2011&amp;summary=yes#jcite">639 F.3d 11</a>, <a href="/s/opinion/9e80f4ac7146e23390fa86e1f038dd82/document/X1F5DQ8003?jcsearch=639%20f%203d%2011&amp;summary=yes#jcite">15</a> (1st Cir.2011) (quoting
<i>Ruiz-Troche v. Pepsi Cola of Puerto Rico Bottling Co.</i>, <a href="/s/opinion/9e80f4ac7146e23390fa86e1f038dd82/document/XACD0K?jcsearch=161%20f%203d%2077&amp;summary=yes#jcite">161 F.3d 77</a>, <a href="/s/opinion/9e80f4ac7146e23390fa86e1f038dd82/document/XACD0K?jcsearch=161%20f%203d%2077&amp;summary=yes#jcite">83</a> (1st
Cir.1998)); <i>see</i> Fed.R.Evid. <a href="/s/opinion/9e80f4ac7146e23390fa86e1f038dd82/document/1?citation=FREVIDEN%20702&amp;summary=yes#jcite">702</a> advisory committee's note (discussing 2000
amendments) ("When a trial court, applying this amendment, rules that an
expert's testimony is reliable, this does not necessarily mean that
contradictory expert testimony is unreliable."). "Vigorous
cross-examination, presentation of contrary evidence, and careful
instruction on the burden of proof are the traditional and appropriate means
of attacking shaky but admissible evidence." <span CLASS="page_no" data-cite="2012 bl 186244 p 6" data-cite-type="Bloomberg" data-cite-pageno="6" data-primary-citation="">[**6]</span> <i>Daubert</i>, <a href="/s/opinion/9e80f4ac7146e23390fa86e1f038dd82/document/X2N776?jcsearch=509%20us%20579&amp;summary=yes#jcite">509 U.S. at 596</a>,
<a href="/s/opinion/9e80f4ac7146e23390fa86e1f038dd82/document/1?citation=113%20supreme%20court%202786&amp;summary=yes#jcite">113 S.Ct. 2786</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The Supreme Court identified in <i>Daubert</i> a number of factors that might
assist the district court in determining the admissibility of expert
evidence: (1) whether the theory or technique applied can be tested, (2)
whether the theory or technique has been subject to peer review or
publication, (3) the known or potential rate of error, and (4) whether it is
accepted in the relevant discipline. <i></i><a href="/s/opinion/9e80f4ac7146e23390fa86e1f038dd82/document/X2N776?jcsearch=509%20U.S.%20579&amp;summary=yes#jcite">Id. at 593-94</a>, <a href="/s/opinion/9e80f4ac7146e23390fa86e1f038dd82/document/1?citation=113%20supreme%20court%202786&amp;summary=yes#jcite">113 S.Ct. 2786</a>. It
instructed district courts to focus on "principles and methodology, not on
the conclusions that they generate." <i></i><a href="/s/opinion/9e80f4ac7146e23390fa86e1f038dd82/document/X2N776?jcsearch=509%20U.S.%20579&amp;summary=yes#jcite">Id. at 595</a>, <a href="/s/opinion/9e80f4ac7146e23390fa86e1f038dd82/document/1?citation=113%20supreme%20court%202786&amp;summary=yes#jcite">113 S.Ct. 2786</a>. The Court
later recognized that "conclusions and methodology are not entirely distinct
from one another." <i>Joiner</i>, <a href="/s/opinion/9e80f4ac7146e23390fa86e1f038dd82/document/X5CCVA?jcsearch=522%20us%20136&amp;summary=yes#jcite">522 U.S. at 146</a>, <a href="/s/opinion/9e80f4ac7146e23390fa86e1f038dd82/document/1?citation=118%20supreme%20court%20512&amp;summary=yes#jcite">118 S.Ct. 512</a>. Accordingly, a
district court's focus on principles and methodology "need not completely
pretermit judicial consideration of an expert's conclusions." <i>Milward</i>,
<a href="/s/opinion/9e80f4ac7146e23390fa86e1f038dd82/document/X1F5DQ8003?jcsearch=639%20f%203d%2011&amp;summary=yes#jcite">639 F.3d at 15</a> (quoting <i>Ruiz-Troche</i>, <a href="/s/opinion/9e80f4ac7146e23390fa86e1f038dd82/document/XACD0K?jcsearch=161%20f%203d%2077&amp;summary=yes#jcite">161 F.3d at 81</a>). Expert evidence may be
excluded if the court determines "that there is simply too great an
analytical gap between the data and the opinion proffered." <i>Joiner, 522.</i>
U.S. at 146, <a href="/s/opinion/9e80f4ac7146e23390fa86e1f038dd82/document/1?citation=118%20supreme%20court%20512&amp;summary=yes#jcite">118 S.Ct. 512</a>.
<span CLASS="page_no" data-cite="686 f 3d 626" data-cite-type="PrimaryFederalReporter" data-cite-pageno="626" data-primary-citation="686 F.3d 618">[*626]</span> 
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  1. WHI Study
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Plaintiffs involved in hormone therapy litigation have long relied on the
WHI study to prove general causation: that is, that use of Prempro increases
the risk of breast cancer. A 2003 article about the WHI study reported:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      For women with no menopausal hormone use before entering the
    study, invasive breast cancer rates were lower for the initial 2
    years in the estrogen plus progestin group compared with placebo,
    and similar in the third year. In the fourth year and thereafter,
    invasive breast cancer rates were higher in the estrogen plus
    progestin group. . . .
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
Ex.App. 55.<a HREF="#fn1200" name="fnref_fn1200">[fn12]</a>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The magistrate judge found that Dr. Austin failed to meet his burden "to
present reliable science to support his conclusion regarding the
unreliability of the WHI." Order of Jan. 19, 2011, at 9. Plaintiffs, as the
proponents of Dr. Austin's testimony, however, do not necessarily have a
burden to disprove the WHI study's finding that short-term use of Prempro
does not increase the risk of breast cancer. Instead, it is their burden to
show that Dr. Austin arrived at his contrary opinion in a scientifically
sound and methodological fashion. If they can meet that burden, the question
becomes one for the jury to decide. <i>See Bonner v. ISP Techs., Inc.</i>,
<a href="/s/opinion/9e80f4ac7146e23390fa86e1f038dd82/document/X512OU?jcsearch=259%20f%203d%20924&amp;summary=yes#jcite">259 F.3d 924</a>, <a href="/s/opinion/9e80f4ac7146e23390fa86e1f038dd82/document/X512OU?jcsearch=259%20f%203d%20924&amp;summary=yes#jcite">930</a> (8th Cir.2001) ("[Q]uestions of conflicting evidence must
be left for the jury's determination.").
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  As an initial matter, we note that the magistrate judge did not address
Dr. Austin's testimony that women who took Prempro had "[L]ower recorded
rates of breast cancer in the first two years, not three years." Hr'g Tr.
152. Dr. Austin distinguished between annual incidents of breast cancer and
cumulative incidents of breast cancer, acknowledging that a graph contained
in a 2006 article showed that the placebo group had higher rates of breast
cancer during the first three years of the trial. See Ex.App. 19.<a HREF="#fn1300" name="fnref_fn1300">[fn13]</a> Dr.
Austin explained that the graph measured cumulative incidents, not annual
incidents, and that it did not plot individual occurrences:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      Now, it is true that if you look at the number of cases occurring
    in a year, not cumulative starting from the beginning, <span CLASS="page_no" data-cite="2012 bl 186244 p 7" data-cite-type="Bloomberg" data-cite-pageno="7" data-primary-citation="">[**7]</span> but how many
    in year one, there were more placebo cases; year two, more placebo
    cases; year three, there were more Prempro cases. So by year three,
    the Prempro group had caught up and even had surpassed. But if you
    look at all three years, they were still behind because they hadn't
    made up for the deficits in year one and two.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
Hr'g Tr. 154. The magistrate judge's opinion addresses only Dr. Austin's
testimony that the cumulative incidents showed no increase in the breast
cancer risk in the first three years. When asked at oral argument before
this court whether the magistrate judge had made a mistake in interpreting
the graph, Wyeth's counsel responded that he had not because the magistrate
judge was interpreting Dr. Austin's testimony, not the underlying evidence,
and because Dr. Austin previously had testified that the WHI study shows no
increased risk when Prempro is taken for three years or less. Dr. Austin's
hearing testimony, however, distinguished between the cumulative and annual
incidents, and any conflict with his previous testimony,
<span CLASS="page_no" data-cite="686 f 3d 627" data-cite-type="PrimaryFederalReporter" data-cite-pageno="627" data-primary-citation="686 F.3d 618">[*627]</span> 
addressed more fully below, presents issues of credibility.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  We conclude that the magistrate judge abused his discretion in deciding
that Dr. Austin's criticisms of the WHI study were unfounded and
inconsistent with his reliance on the study in other hormone therapy cases.
When asked by the court how the WHI could be the "gold standard" to show
that E + P is a carcinogen but could not be relied upon to show that its
short-term use does not increase the risk of breast cancer, Dr. Austin
replied that the WHI study was an ideal study design &mdash; "the gold standard
for what it was designed for" &mdash; but that it was designed to show what effect
E + P had on heart disease. Hr'g Tr. 69. He explained that although the
study monitored incidents of breast cancer, the women were not selected to
test whether Prempro causes breast cancer. According to Dr. Austin, this
resulted in a study population that was at a much lower risk because (1) the
study discouraged the participation of women with moderate menopausal
symptoms and (2) the participants had a longer gap time between menopause
and beginning hormone therapy treatment than women who begin hormone therapy
on their own volition. Dr. Austin went on to explain that, despite its
shortcomings, the study showed that E + P causes breast cancer:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      Now, with all of these disadvantages, it still showed that after
    five years, the E plus P group had a statistically significantly
    higher risk, and so high that they had to stop the study. So with
    all those things against it, it still demonstrated cause, even the
    way they analyzed it, the fact they didn't use gap time, the fact
    that they picked women that are not really representative of the
    general population who use E plus P. In spite of all those things,
    they still found it was a cause and demonstrated it was a cause.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<i></i><cite>Id. at 69-70</cite>. In light of this testimony and its supporting evidence, Dr.
Austin's reliance on the WHI study to prove general causation does not
foreclose his opinion that the study did not accurately assess the risk of
breast cancer associated <span CLASS="page_no" data-cite="2012 bl 186244 p 8" data-cite-type="Bloomberg" data-cite-pageno="8" data-primary-citation="">[**8]</span> with the short-term use of Prempro.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The magistrate judge also found that Dr. Austin previously had
contradicted his opinion that the WHI study lacked power to detect an
increased risk of breast cancer from short-term use of Prempro. The court
noted that "previously, Dr. Austin agreed that WHI, as a clinical trial, had
the greatest power when assessing HRT [hormone therapy] and women's health."
Order of Jan. 19, 2011, at 7. Dr. Austin now offers a more nuanced opinion
than he has in the past, setting forth the foundation for his present
concerns, for as he explained,
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      Well, that's because there's two separate concepts. One is, is it
    a cause or not? And the other one is, what is the risk estimate? And
    observational studies have different strengths and weaknesses on
    those two points. They're not as good for demonstrating cause and
    effect, but they're much better at estimating the size of the risk.
    So different study designs are used to try to do different things,
    and in this [WHI], even though it wasn't designed to see what the
    effect on breast cancer was, it did, and the causal nature was
    demonstrated and it's irrefutable.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
Hr'g Tr. 71-72.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Wyeth will certainly challenge Dr. Austin's credibility based on his
previous testimony, including his agreement that the WHI study would be a
"good study to look at in determining whether a certain duration of exposure
to Prempro increases the risk of breast cancer." <i></i><cite>Id. at 145</cite>. But his
previous reliance on and testimony regarding the WHI study does not render
his
<span CLASS="page_no" data-cite="686 f 3d 628" data-cite-type="PrimaryFederalReporter" data-cite-pageno="628" data-primary-citation="686 F.3d 618">[*628]</span> 
opinion inadmissible, as it was not his burden to disprove the Will's
finding that short-term use of Prempro does not increase the risk of breast
cancer.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Finally, in determining that Dr. Austin failed to support his criticisms
of the WHI study, the magistrate judge found that Dr. Austin's opinions were
"hastily formed in an attempt to overcome overwhelmingly reliable evidence
to the contrary." Order of January 19, 2011, at 9. Dr. Austin testified that
the short-term use issue was presented to him shortly before the <i>Daubert</i>
hearing in Puerto Rico. He wrote the expert report in approximately five
hours, with the assistance of Plaintiffs' counsel. The magistrate judge's
concerns about Dr. Austin's opinions, however, go to his credibility as a
witness, not to the admissibility of his testimony as an expert. Wyeth
argues that, like the expert testimony in <i>In re TMI Litigation</i>, <a href="/s/opinion/9e80f4ac7146e23390fa86e1f038dd82/document/X3OD2O?jcsearch=193%20f%203d%20613&amp;summary=yes#jcite">193 F.3d 613</a>
(3d Cir.1999), Dr. Austin's testimony should be excluded based on his
reliance on Plaintiffs' counsel. In that case, however, the expert relied on
medical history summaries prepared at the direction of plaintiffs' counsel,
which the court found unreliable. <i></i><a href="/s/opinion/9e80f4ac7146e23390fa86e1f038dd82/document/X3OD2O?jcsearch=193%20F.3d%20613&amp;summary=yes#jcite">Id. at 697-98</a>. Here, Dr. Austin relied on
epidemiological studies that, at most, were compiled for him by Plaintiffs'
counsel. Unlike the medical history summaries, the supporting observational
studies provide adequate foundation for Dr. Austin's testimony.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  2. Supporting Observational Studies
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Dr. Austin ultimately relied on three observational studies to support his
opinion: the Calle study, the Million Women Study, and the Fournier study.
The magistrate judge <span CLASS="page_no" data-cite="2012 bl 186244 p 9" data-cite-type="Bloomberg" data-cite-pageno="9" data-primary-citation="">[**9]</span> analyzed each study separately and concluded that the
studies failed to reliably support Dr. Austin's position. On appeal, Kuhn
and Davidson argue that the magistrate judge usurped the role of factfinder
and that any problems with the studies go to the weight of the evidence, not
to the studies' validity. Wyeth responds that the magistrate judge properly
determined that the studies were insufficient to support Dr. Austin's
opinion because there existed too great an analytical gap between the
underlying studies and Dr. Austin's opinion, <i>see Joiner</i>, <a href="/s/opinion/9e80f4ac7146e23390fa86e1f038dd82/document/X5CCVA?jcsearch=522%20us%20136&amp;summary=yes#jcite">522 U.S. at 146-47</a>,
<a href="/s/opinion/9e80f4ac7146e23390fa86e1f038dd82/document/1?citation=118%20supreme%20court%20512&amp;summary=yes#jcite">118 S.Ct. 512</a>, and because in relying on the studies, he failed to employ
the rigorous methods that he uses in other contexts, <i>see Kumho Tire Co.</i>,
<a href="/s/opinion/9e80f4ac7146e23390fa86e1f038dd82/document/X2N7BT?jcsearch=526%20us%20137&amp;summary=yes#jcite">526 U.S. at 152</a>, <a href="/s/opinion/9e80f4ac7146e23390fa86e1f038dd82/document/1?citation=119%20supreme%20court%201167&amp;summary=yes#jcite">119 S.Ct. 1167</a>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  a. Calle Study
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Dr. Austin relied on the Calle study, a study of 67, 754 American women
that "examined prospectively the relation between postmenopausal hormone use
and the risk of incident of breast cancer. . . ." Ex. App 32. When the
participants enrolled in 1992, they completed self-administered mailed
questionnaires that collected information regarding demographic, medical,
behavioral, environmental, occupational, and dietary factors. Follow-up
questionnaires were sent in 1997, 1999, 2001, and 2003 "to update exposure
information and to ascertain newly diagnosed cancers." <i><cite>Id</cite>.</i> According to the
authors, "[i]nformation regarding postmenopausal hormone use was collected
at the time of enrollment and on all follow-up questionnaires." <i></i><cite>Id. at 33</cite>.
Women with unknown type or duration of hormone use were excluded from the
analysis. The authors observed no increase in risk with use of E + P in the
first two years of use. "However, we observed a significant increase in risk
for both types of breast cancer at 2 to 3 years of use . . . and all years
thereafter." <i></i><cite>Id. at 37</cite>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The magistrate judge found the study unreliable because "there was no way
to measure how it accounted for previous use [of hormone therapy]" and
because it
<span CLASS="page_no" data-cite="686 f 3d 629" data-cite-type="PrimaryFederalReporter" data-cite-pageno="629" data-primary-citation="686 F.3d 618">[*629]</span> 
failed to meet Dr. Austin's criteria to characterize exposure "carefully and
accurately." Order of Jan. 19, 2011, at 17. Plaintiffs argue that the
magistrate judge erred in finding that the study failed to monitor exposure
and duration of use. We agree. As set forth above, the study explains that
women with unknown type or duration of hormone use were excluded from the
analysis and that the authors gathered information regarding hormone therapy
use at the time of enrollment and again in 1997, 1999, 2001, and 2003.<a HREF="#fn1400" name="fnref_fn1400">[fn14]</a>
Consistent with the study, Dr. Austin testified that he believed that
information regarding breast cancer occurrence and duration of hormone
therapy use was collected in each follow-up questionnaire.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  b. Foreign Studies
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Dr. Austin also relied on two foreign studies: the Million Women Study
from England and the Fournier study from France. "The Million Women Study
was set up to investigate the effects of specific types of [hormone therapy]
on incident and fatal breast cancer." Ex.App. 165. As its name suggests, the
study involved more than one million women between fifty and sixty-four
years of age, including more than 20,000 participants who took
medroxyprogesterone <span CLASS="page_no" data-cite="2012 bl 186244 p 10" data-cite-type="Bloomberg" data-cite-pageno="10" data-primary-citation="">[**10]</span> acetate combined with conjugated equine estrogen, the
same formulation as Prempro. It found that combined estrogen and progestin
therapy increased the risk of breast cancer and that "[r]esults varied
little between specific oestrogens and progestagens or their doses; or
between continuous and sequential regimens." <i><cite>Id</cite>.</i> Specifically, the study
reported:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      Other than the substantial difference between the effects of
    oestrogen-only and oestrogen-progestagen combinations, these results
    suggest no large variations between the effects of specific
    oestrogens (equine oestrogen and oestradiol) or between specific
    progestagens (medroxyprogesterone acetate, norgestrel, and
    norethisterone). They also suggest that results on the risk of
    breast cancer for the specific constituents used in the Women's
    Health Initiative trial do not differ materially from the results
    for other oestrogen-progestagen combinations.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<i></i><cite>Id. at 172</cite>. Upon joining the Million Women Study, the participants reported
information regarding their hormone therapy use including their "ever use;
current use; age at first and last use; total duration of use; and the name
of the proprietary preparation used most recently and duration of its use."
<i></i><cite>Id. at 165</cite>. The participants thus reported their duration of use when they
enrolled, but the study did not measure their use after enrollment. Instead,
it found that "[t]he breast cancers were diagnosed on average 1.2 years
after recruitment" to the study. <i></i><cite>Id. at 167</cite>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  A table in the Million Women Study shows an elevated relative risk of
breast cancer among women who reported using estrogen plus progestagen for
less than one year. Because the study measured duration of use at enrollment
rather than diagnosis, the precise duration of use by those women diagnosed
with breast cancer was unknown. Dr. Austin suggested that by adding the
average 1.2 years from enrollment to diagnosis to the less than one
<span CLASS="page_no" data-cite="686 f 3d 630" data-cite-type="PrimaryFederalReporter" data-cite-pageno="630" data-primary-citation="686 F.3d 618">[*630]</span> 
year of use, the study supported his short-term use opinion because it
showed an elevated risk in less than 2.2 years. He testified that, "we have
very large numbers here, and small amounts of misclassifications don't
really make a lot of difference." Hr'g Tr. 27.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Dr. Austin also relied upon the Fournier study, which investigated
"whether the relation between estrogen-progestagen menopausal hormone
therapy (EP-MHT) and breast cancer risk varies according to the delay
between menopause onset and treatment initiation." Ex.App. 83. More than
50,000 postmenopausal French women participated in the study. The results
suggested that "in recent users of some EPMHT, the timing of treatment
initiation modulates the risk of breast cancer: short durations (&le;2 years)
of use were associated with significant increases in risk &mdash; with the
exception of MHT containing progesterone &mdash; when initiated in the 3-year
period following menopause, but not when initiated later."<a HREF="#fn1500" name="fnref_fn1500">[fn15]</a><i>Id.</i> at
86-87. In other words, as Dr. Austin explained, the study showed an
increased risk of breast cancer in women taking hormone therapy for less
than two years when the women began <span CLASS="page_no" data-cite="2012 bl 186244 p 11" data-cite-type="Bloomberg" data-cite-pageno="11" data-primary-citation="">[**11]</span> hormone therapy shortly after the onset
of menopause.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  French women typically use a different type of hormone therapy than
American women. In the Fournier study's cohort, "the estrogenic component
consisted almost exclusively of estradiol compounds, with progesterone and
dydrogesterone as the most frequently associated progestagens." <i>Id.</i> at 87.
Although relatively few participants took formulations comprised of
conjugated estrogens combined with medroxyprogesterone acetate, like
Prempro, more than one hundred participants using hormone therapy comprised
of progestagens were diagnosed with breast cancer.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      With more than 100 participants diagnosed with breast cancer among
    those using EP-MHT (containing progestagens other than progesterone
    or dydrogesterone) for 2 years or less, we found significant
    doubling in risk when the MHT began within 3 years of menopause
    compared with MHT never use. For the other durations of use,
    estimates of the WHI and ours are consistent.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      Our results of breast cancer risks increased even with relatively
    short durations of some EP-MHT are consistent with epidemiological
    studies that found significant increases in risk for current or
    recent short-term (&lt; 5 years) use of EP-MHT, although some did not
    find significant increases.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<i>Id.</i> In an editorial commenting on the Fournier study, Leslie Bernstein,
M.D., thus wrote, "[I]t will be important for other cohorts that focus on
use of HT in United States populations to evaluate breast cancer risk
associated use immediately after menopause." <i>Id.</i> at 28.<a HREF="#fn1600" name="fnref_fn1600">[fn16]</a>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Dr. Austin acknowledged that the Fournier study did not separate Prempro's
formulation from other hormone therapy formulations. He testified that
medroxyprogesterone acetate is combined only with conjugated estrogens and
that its risk estimates are similar to those of other of synthetic
progesterones that are combined with other estrogens. "Since
<span CLASS="page_no" data-cite="686 f 3d 631" data-cite-type="PrimaryFederalReporter" data-cite-pageno="631" data-primary-citation="686 F.3d 618">[*631]</span> 
we look at them separately and they're similar, I think no violence is done
to the analysis by combining them." Hr'g Tr. 119. On cross-examination,
however, Dr. Austin was confronted with an expert report he authored in
2007, wherein he opined that estradiol and conjugated equine estrogen should
be considered separately "to determine if they have statistically different
long-term effects." <i>Id.</i> at 117. When asked if that same analysis should be
done to determine the short-term effects, Dr. Austin responded, "It's the
most ideal, yes. . . . Fournier did not do that." <i>Id.</i> Dr. Austin also
acknowledged that the Fournier study provided no separate analysis of
Prempro formulation at three years or less.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The magistrate judge concluded that the foreign studies did not reliably
support Dr. Austin's opinion because most participants in the studies took
hormone therapy formulations other than Prempro and because the studies did
not analyze Prempro separately from other hormone therapy formulations after
three years.<a HREF="#fn1700" name="fnref_fn1700">[fn17]</a> With respect to the Million Women Study, the magistrate
judge determined that the study's failure to accurately assess years of use
rendered <span CLASS="page_no" data-cite="2012 bl 186244 p 12" data-cite-type="Bloomberg" data-cite-pageno="12" data-primary-citation="">[**12]</span> the study unreliable. The court found Dr. Austin's suggestion to
add the "average underestimate of 1.2 years" use irreconcilable with "his
position that when looking at short-term use, one must be quite precise in
the analysis." Order of Jan. 19, 2011, at 16.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Although the foreign studies have important limitations, they nonetheless
provide support for Dr. Austin's opinion. As set forth above, the Million
Women Study explained that there exists no material difference in risk among
the combined estrogen and progestin hormone therapy formulations, including
Prempro. With this finding, and its finding that less than one year's use of
combined hormone therapy increases the risk of breast cancer, the Million
Women Study provides support for Dr. Austin's opinion regarding short-term
use. Likewise, the differences between Prempro and the French combined
hormone therapy formulation do not render the study unreliable to support
Dr. Austin's opinion.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Citing <i>Glastetter v. Novartis Pharmaceuticals Corp.</i>, <a href="/s/opinion/9e80f4ac7146e23390fa86e1f038dd82/document/X50TBA?jcsearch=252%20f%203d%20986&amp;summary=yes#jcite">252 F.3d 986</a> (8th
Cir.2001) (per curiam), Wyeth argues that Dr. Austin's testimony relating
the European formulations to the American formulations constitutes an
unsupported assumption. In <i>Glastetter</i>, the plaintiffs experts hypothesized
that the chemical at issue, bromocriptine, "may behave like its chemical
cousins," ergot alkaloids, which were known to cause a condition that was a
known risk factor for the plaintiffs injury. <i></i><a href="/s/opinion/9e80f4ac7146e23390fa86e1f038dd82/document/X50TBA?jcsearch=252%20F.3d%20986&amp;summary=yes#jcite">Id. at 989-90</a>. We concluded
that the "generic assumption that bromocriptine behaves like other ergot
alkaloids carries little scientific value." <i></i><a href="/s/opinion/9e80f4ac7146e23390fa86e1f038dd82/document/X50TBA?jcsearch=252%20F.3d%20986&amp;summary=yes#jcite">Id. at 990</a>. Here, Dr. Austin
presented evidence that the Million Women Study considered estrogen plus
progestin hormone therapy formulations separately and found little
difference between the effects of the different formulations.<a HREF="#fn1800" name="fnref_fn1800">[fn18]</a> His
testimony was thus not a "generic assumption," but rather was supported by
the study's findings.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span CLASS="page_no" data-cite="686 f 3d 632" data-cite-type="PrimaryFederalReporter" data-cite-pageno="632" data-primary-citation="686 F.3d 618">[*632]</span> 
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Along with the different formulations, we recognize that the Million Women
Study's computation of duration of use is imprecise and that the "average
underestimate of 1.2 years" is disputed. Like the formulation differences,
the duration issues, however, do not create so great an analytical gap
between the data and the opinion as to render the opinion inadmissible.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  As set forth above, the magistrate judge relied on Dr. Austin's testimony
in other cases and his earlier statements to find that the foreign studies
did not reliably support his opinion. Specifically, the court found that the
studies failed to meet Dr. Austin's criteria of (1) accurately
characterizing exposure to the drug, (2) identifying the specific drug
formulations, and (3) analyzing the Prempro formulation separately. At the
hearing, Dr. Austin acknowledged that, ideally, a study would measure
exposure precisely and analyze the Prempro formulation separately, but he
did not concede that the studies on which he based his opinion were
unreliable. Instead, he explained,
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      [The foreign studies] give us information that other studies don't
    because of their large number, and the fact that, <span CLASS="page_no" data-cite="2012 bl 186244 p 13" data-cite-type="Bloomberg" data-cite-pageno="13" data-primary-citation="">[**13]</span> like in this one,
    where they were able to eliminate the gap time, they are imperfect
    in that they mix together drugs of similar types so that it loses
    its specificity. But it does gain in the fact that they have large
    numbers for the things that we're interested in with short-term use.
    So although there's no study that's perfect that I'm aware of for
    answering this specific question, the fact that these two studies
    are consistent in their findings is important.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
Hr'g Tr. 51-52. Although the foreign studies are not perfect, they provide
useful information that, along with the Calle study, provides an adequate
foundation for Dr. Austin's opinion. His prior testimony may well call his
credibility into question, but it does not prove that he failed to follow
his own general practice or that he relied on unfounded assumptions in his
analysis. <i>Cf. Junk</i>, <a href="/s/opinion/9e80f4ac7146e23390fa86e1f038dd82/document/X1EMNS8003?jcsearch=628%20f%203d%20439&amp;summary=yes#jcite">628 F.3d at 448</a> (holding that the expert's "failure to
follow his own general practice and his reliance on unfounded assumptions in
his comparative method created `too great an analytical gap' between his
opinion and the data on which it relied" (quoting <i>Joiner</i>, <a href="/s/opinion/9e80f4ac7146e23390fa86e1f038dd82/document/X5CCVA?jcsearch=522%20us%20136&amp;summary=yes#jcite">522 U.S. at 146</a>,
<a href="/s/opinion/9e80f4ac7146e23390fa86e1f038dd82/document/1?citation=118%20supreme%20court%20512&amp;summary=yes#jcite">118 S.Ct. 512</a>)); <i>Fireman's Fund Ins. Co. v. Canon U.S.A., Inc.</i>,
<a href="/s/opinion/9e80f4ac7146e23390fa86e1f038dd82/document/XGFNH3?jcsearch=394%20f%203d%201054&amp;summary=yes#jcite">394 F.3d 1054</a>, <a href="/s/opinion/9e80f4ac7146e23390fa86e1f038dd82/document/XGFNH3?jcsearch=394%20f%203d%201054&amp;summary=yes#jcite">1059</a> (8th Cir.2005) (noting that the sudden reversal of
opinion regarding the meaning of burn pattern evidence "seriously
undermine[d] the reliability of the experts' opinions").
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  c. Supporting Observational Studies Sufficient to Support Dr. Austin's
Opinion
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Dr. Austin's testimony is admissible because the studies upon which he
relied were sufficient to support his opinion that short-term use of Prempro
increases the risk of breast cancer. Taken together, the Calle study and the
foreign studies constitute appropriate validation of and good grounds for
Dr. Austin's opinion. The studies' limitations may be presented to the jury,
and Dr. Austin's reliance on the studies may be tested through the
traditional means of cross examination and presentation of contrary
evidence.<a HREF="#fn1900" name="fnref_fn1900">[fn19]</a>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span CLASS="page_no" data-cite="686 f 3d 633" data-cite-type="PrimaryFederalReporter" data-cite-pageno="633" data-primary-citation="686 F.3d 618">[*633]</span> 
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  3. Wyeth's "Cherry Picking" Allegation
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Wyeth argues that Dr. Austin "cherry picked" the Calle study and the two
foreign studies from a wealth of studies showing no increased risk of breast
cancer from short-term Prempro use. Wyeth compares this case to <i>Norris v.</i>
<i>Baxter Healthcare Corp.</i>, <a href="/s/opinion/9e80f4ac7146e23390fa86e1f038dd82/document/XVNV1R?jcsearch=397%20f%203d%20878&amp;summary=yes#jcite">397 F.3d 878</a> (10th Cir.2005), in which the
defendant presented at least seventeen epidemiological studies in support of
its contention that silicone breast implants do not cause disease. The
plaintiffs in <i>Norris</i> offered no epidemiological studies to support their
contrary position, instead relying upon differential diagnosis and case
studies. The <i>Norris</i> court concluded that "[p]laintiffs experts' differential
diagnoses and case studies are unreliable because they assume what science
has largely shown does not exist-a causal connection between silicone breast
implants and disease." <i></i><a href="/s/opinion/9e80f4ac7146e23390fa86e1f038dd82/document/XVNV1R?jcsearch=397%20F.3d%20878&amp;summary=yes#jcite">Id. at 886</a>. Unlike those experts, Dr. Austin has
presented reliable epidemiological evidence to support his opinion that
short-term use of Prempro increases the risk of breast cancer. There may be
several studies supporting Wyeth's contrary position, but it is not the
province of the court to <span CLASS="page_no" data-cite="2012 bl 186244 p 14" data-cite-type="Bloomberg" data-cite-pageno="14" data-primary-citation="">[**14]</span> choose between the competing theories when both are
supported by reliable scientific evidence.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  B. Summary Judgment
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  The grant of summary judgment in favor of Wyeth was based on the
preclusion of Dr. Austin's opinion. Because we hold Dr. Austin's opinion is
admissible, we reverse the order granting summary judgment.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  III. Conclusion
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  We reverse the orders granting Wyeth's motions to preclude expert
testimony and for summary judgment. Because our reversal is based on the
conclusion that Dr. Austin's opinion is admissible, we do not reach the
merits of Kuhn's argument that the <i>Daubert</i> order did not apply to her
because she had used Prempro for more than three years. The case is remanded
for further proceedings.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn100" name="fn100">[fn1]</a></span> This opinion uses the name "Wyeth" to refer to the named defendants,
Wyeth, Inc.; Wyeth Pharmaceuticals, Inc.; and Wyeth.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn200" name="fn200">[fn2]</a></span> Medroxyprogesterone acetate is a progestin. <i>Borland's Illustrated</i>
<i>Medical Dictionary</i> 1137 (31st ed. 2007). Progestin, also called progestogen,
is a progestational agent, meaning that it has effects similar to those of
progesterone. <i></i><cite>Id. at 39</cite>, 1546. Progesterone is "the principal progestational
hormone of the body . . . it prepares the uterus for the reception and
development of the fertilized oocyte . . . and maintains an optimal
intrauterine environment for sustaining pregnancy." <i></i><cite>Id. at 1546</cite>.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn300" name="fn300">[fn3]</a></span> "The Women's Health Initiative (WHI) focuses on defining the risks and
benefits of strategies that could potentially reduce the incidence of heart
disease, breast and colorectal cancer, and fractures in postmenopausal
women." Jacques E. Rossouw et al., <i>Risks and Benefits of Estrogen Plus</i>
<i>Progestin in Healthy Postmenopausal Women</i>, 288 JAMA 321, 321 (2002).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn400" name="fn400">[fn4]</a></span> The motion to preclude was filed before case-specific discovery had
been completed and before the parties had designated their experts.
Accordingly, Wyeth did not challenge Plaintiffs' expert's opinions and
methodologies, but rather tried to anticipate their position.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn500" name="fn500">[fn5]</a></span> Statistical power is "the probability of rejecting the null hypothesis
in a statistical test when a particular alternative hypothesis happens to be
true." <i>Merriam-Webster Collegiate Dictionary</i> 973 (11th ed. 2003). In other
words, it is the probability of observing false negatives. Power analysis
can be used to calculate the likelihood of accurately measuring a risk that
manifests itself at a given frequency in the general population based on the
sample size used in a particular study. Such an analysis is distinguishable
from determining which study among several is the most reliable for
evaluating whether a correlative or even a causal relationship exists
between two variables.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn600" name="fn600">[fn6]</a></span> Gap time is the time from menopause onset to treatment initiation. <i>See</i>
Hr'g Tr. 48. Throughout this opinion, Hr'g Tr. refers to the transcript of
the January 12, 2011, <i>Daubert</i> hearing.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn700" name="fn700">[fn7]</a></span> Dr. Austin also opined that studies employing "ever used" as the
measure of exposure were unreliable because they included both women who
were taking E + P during the study and those who were not. He explained that
because the risk for women who had ceased using E + P would have returned to
a baseline risk, those cases were not suitable for assessing short-term
risk. Dr. Austin also would not rely upon studies that analyzed conjointly
the risk of E + P and E-only because "the causal effect of estrogen alone on
the breast is considerably less than that of E + P." Kuhn App. 3900.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn800" name="fn800">[fn8]</a></span> During the first three years of the study, twenty-three percent of the
participants dropped out.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn900" name="fn900">[fn9]</a></span> Although the Calle study was not cited in Dr. Austin's expert report,
it was cited in Plaintiffs' opposition to Wyeth's motion to exclude, and Dr.
Austin testified regarding the Calle study during the January 2011 <i>Daubert</i>
hearing. When quoting material from the articles describing these studies,
we will cite Kuhn's Exhibit Appendix, hereinafter Ex.App. Those articles
include the following: Agnes Fournier et al., <i>Estrogen-Progestagen</i>
<i>Menopausal Hormone Therapy and Breast Cancer: Does Delay From Menopause</i>
<i>Onset to Treatment Initiation Influence Risks?</i>, J. Clinical Oncology
(published online ahead of print on Sept. 14, 2009); Eugenia E. Calle et
al., Post-<i>menopausal Hormone Use and Breast Cancer Associations Differ by</i>
<i>Hormone Regimen and Histologic Subtype</i>, Cancer 936 (Mar. 1, 2009); <i>Breast</i>
<i>cancer and hormone-replacement therapy in the Million Women Study</i>, 362
Lancet 419 (Aug. 9, 2003).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn1000" name="fn1000">[fn10]</a></span> Identical orders were filed in both Kuhn's and Davidson's cases.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn1100" name="fn1100">[fn11]</a></span> Wyeth did not challenge Dr. Austin's qualifications or the general
practice of relying on epidemiological studies to support an expert
opinion.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn1200" name="fn1200">[fn12]</a></span> Rowan T. Chlebowski et al., <i>Influence of Estrogen Plus Progestin on</i>
<i>Breast Cancer and Mammography in Healthy Postmenopausal Women</i>, 289 JAMA 3243
(2003).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn1300" name="fn1300">[fn13]</a></span> Garnet L. Anderson et al., <i>Prior hormone therapy and breast cancer</i>
<i>risk in the Women's Health Initiative randomized trial of estrogen plus</i>
<i>progestin</i>, Maturitas (2006).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn1400" name="fn1400">[fn14]</a></span> The participants returned self-administered questionnaires to report
their hormone use, and Dr. Austin testified that self-reporting lends itself
to some error. We note that the WHI study assessed some breast cancer risk
factors and initial reports of cancer outcomes by self-administered
questionnaires. Ex.App. 53. Based on the reliance on the WHI study by all
the parties in this case, we conclude that self-reporting alone does not
render a study unreliable in this context.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn1500" name="fn1500">[fn15]</a></span> The Fournier study observed that using progesterone may be safer than
other progestagens, but that the finding "needs to be confirmed in other
settings." Ex.App. 88.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn1600" name="fn1600">[fn16]</a></span> Leslie Bernstein, <i>Combined Hormone Therapy at Menopause and Breast</i>
<i>Cancer: A Warning</i> &mdash; <i>Short-Term Use Increases Risk</i>, J. Clinical Oncology
(published online ahead of print on Sept. 14, 2009).
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn1700" name="fn1700">[fn17]</a></span> The Million Women Study considered separately participants' use of
Prempro for five years or less and found that the relative risk of breast
cancer was 1.62. The magistrate judge found this analysis unhelpful because
"the issue before the Court involves usages of around three years or fewer;
the MWS did not separately assess Prempro for around three years or fewer."
Order of Jan. 19, 2011, at 15.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn1800" name="fn1800">[fn18]</a></span> We note that the magistrate judge did not address the study's finding
that results varied little between specific estrogen plus progestin hormone
therapy formulations.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
<span class="fr"><a HREF="#fnref_fn1900" name="fn1900">[fn19]</a></span> In his expert report, Dr. Austin opined that E + P is "both a
promoter and a growth stimulant, meaning its effect is both to cause new
cancers to occur, and to cause [estrogen receptive] tumors to grow more
quickly." Kuhn App. 3904. Accordingly, he opined that the effect of E + P on
cell proliferation is "almost immediate." <i><cite>Id</cite>.</i> Because we conclude that Dr.
Austin's opinion is adequately supported by epidemiological studies, we do
not address Plaintiffs' argument that "basic biology confirms the causal
associations shown by several epidemiological studies." Kuhn Br. 70.
</p></div>
</div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  LOKEN, Circuit Judge, dissenting.
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Early in its lengthy analysis, the district court described the
"methodology" of plaintiffs' expert, Dr. Donald Austin:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      according to Dr. Austin, his short-term use report was written in
    about five hours at the behest and assistance of Plaintiffs'
    counsel. Dr. Austin testified that he had never really thought about
    the short-term use issue before Plaintiffs' counsel presented it to
    him shortly before the recent <i>Daubert</i> challenge in Puerto Rico. He
    testified, "[i]t had never been raised as an issue to me, is there
    an important, a biologically important and clinically important risk
    within three years. It was just not an issue that I had thought
    about."
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
After thoroughly reviewing the bases for Dr. Austin's opinion in an analysis
the court now finds statistically faulty in some respects, the district
court concluded:
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
      Dr. Austin contends that short-term use of Prempro causes breast
    cancer, and cites five studies to support his conclusions. However,
    he conceded the following: two of the studies he admitted should not
    have been included in his report (Li (2000) and Saxena (2010)); two
    of the studies primarily involved drug combinations that were not
    Prempro (MWS [Million Women Study], French Teachers Study
    [Fournier]); and one of the studies did not reliably
<span CLASS="page_no" data-cite="686 f 3d 634" data-cite-type="PrimaryFederalReporter" data-cite-pageno="634" data-primary-citation="686 F.3d 618">[*634]</span> 
    track duration of use, which is essential when making a short-term
    use causation finding (Calle (2009)). With no studies to reliably
    support his position, along with a failed effort to discredit WHI
    results, Dr. Austin's opinion on short-term use causation [is] not
    sufficiently reliable to be admissible under <i>Daubert.</i>
</p></div>
<div id="paraOpinion" printdualcolumn="true"><p class="opinion_text">
  Like the district court in <i>General Electric Co. v. Joiner</i>, <a href="/s/opinion/9e80f4ac7146e23390fa86e1f038dd82/document/X5CCVA?jcsearch=522%20us%20136&amp;summary=yes#jcite">522 U.S. 136</a>,
<a href="/s/opinion/9e80f4ac7146e23390fa86e1f038dd82/document/1?citation=118%20supreme%20court%20512&amp;summary=yes#jcite">118 S.Ct. 512</a>, <a href="/s/opinion/9e80f4ac7146e23390fa86e1f038dd82/document/X5CCVA?jcsearch=139%20l%20ed%202d%20508&amp;summary=yes#jcite">139 L.Ed.2d 508</a> (1997), the district court excluded opinion
testimony of plaintiffs' only expert. In my view, the district court's
<i>Daubert</i> analysis is supported by the record and properly focused on the
gate-keeping function mandated by the Supreme Court and by Rule 702. We
review that ruling for abuse of discretion and must affirm unless it is
"manifestly erroneous." <i>Joiner</i>, <a href="/s/opinion/9e80f4ac7146e23390fa86e1f038dd82/document/X5CCVA?jcsearch=522%20us%20136&amp;summary=yes#jcite">522 U.S. at 142</a>, <a href="/s/opinion/9e80f4ac7146e23390fa86e1f038dd82/document/1?citation=118%20supreme%20court%20512&amp;summary=yes#jcite">118 S.Ct. 512</a>. We may not
subject the ruling to "a more searching standard of review" because it was
"`outcome determinative.'" <i></i><a href="/s/opinion/9e80f4ac7146e23390fa86e1f038dd82/document/X5CCVA?jcsearch=522%20U.S.%20136&amp;summary=yes#jcite">Id. at 142-43</a>, <a href="/s/opinion/9e80f4ac7146e23390fa86e1f038dd82/document/1?citation=118%20supreme%20court%20512&amp;summary=yes#jcite">118 S.Ct. 512</a>. I conclude that,
like our sister circuit the Supreme Court reversed in Joiner, the court has
"appl[ied] an overly `stringent' review to that ruling [and] failed to give
the trial court the deference that is the hallmark of abuse of discretion
review." <i></i><a href="/s/opinion/9e80f4ac7146e23390fa86e1f038dd82/document/X5CCVA?jcsearch=522%20U.S.%20136&amp;summary=yes#jcite">Id. at 143</a>, <span CLASS="page_no" data-cite="2012 bl 186244 p 15" data-cite-type="Bloomberg" data-cite-pageno="15" data-primary-citation="">[**15]</span> <a href="/s/opinion/9e80f4ac7146e23390fa86e1f038dd82/document/1?citation=118%20supreme%20court%20512&amp;summary=yes#jcite">118 S.Ct. 512</a>. Accordingly, I respectfully dissent.
</p></div>
<!--BBLS DD 1719302946819-->

</div>
<div class='sideBar printHide clearfix '>
<!-- /Default state -->
<!-- /Display properties -->
<div class='tabsNotepad printHide'>
<div class='tabButtons clearfix'>
<div class='borderTab activeTab' id='buttonTab_general'>
<span>
General Info
</span>
</div>
<div class='borderTab inactiveTab' id='buttonTab_notePad'>
<span>Notepad</span>
</div>
</div>
</div>
<div class='sideBarInner clearfix'>
<div class='sideBarContent bootstrap sidebar ' id='tab_general'>
<div class='sidebarSection'>
<div class='sidebarTitle'>
<span class='left'>BCite Analysis</span>
</div>
<div class='sidebarSubsection sidebarSectionDivider bciteRenderer clearfix'>
<div class='sidebarSubhead bold'>
<a href="/bcite/X1I1772003/history">Direct History (286)</a>
</div>
<div class='sidebarItemLabel bold'>
No Negative Direct History
</div>
</div>
<div class='bciteRenderer clearfix sidebarSectionDivider sidebarSubsection'>
<div class='sidebarSubhead bold'>
<a href="/bcite/X1I1772003/analysis">Case Analysis (13)</a>
</div>
<div class='bciteResult'>
<img class='icon printOnly' src='/images/citation_icons/positive.png'>
<div class='citation icon positive printHide' title='Positive'></div>
<a class='citationAnalysisLabel' href='/bcite/X1I1772003/analysis?analysis=BCITE_POSITIVE_GROUP'>
Positive
</a>
<span class='citationNumberLabel'>
13
</span>
</div>
</div>
<div class='sidebarSubsection clearfix analysisLink'>
<div class='sidebarSubhead small'>
<a href="https://www.bloomberglaw.com/help/BCite_Indicators.htm" class="citatorRenderer">Description of BCite Indicators</a>
</div>
</div>

<div id='generalInfo'>
<div class='sidebarSection'>
<div class='sidebarTitle'>
<span>
General Information
</span>
</div>
<div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Result(s)</div><div class='facetItemLabel'>Order Reversed, Case Remanded</div></div>
<div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Industries</div><div class='facetItemLabel'>Health &amp; Medical</div></div><div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Related Docket(s)</div><div class='facetItemLabel'><a href="/s/opinion/9e80f4ac7146e23390fa86e1f038dd82/document/X1Q6LJ7JID82">11-01809 (8th Cir.)</a></div><div class='facetItemLabel'><a href="/s/opinion/9e80f4ac7146e23390fa86e1f038dd82/document/X1Q6LJ7JIJ82">11-01815 (8th Cir.)</a></div></div><div class='sidebarSubsection sidebarSectionDivider'><div class='facetItemHeading'>Topic(s)</div><div class='facetItemLabel'>Evidence</div><div class='facetItemLabel'>Health Law</div></div>
<div class='sidebarSubsection' id='judges_section'>
<div class='facetItemHeading'>Judge(s)</div>
<div id='judges_section_loader'></div>
</div>
</div>
</div>
</div>
</div>
<div class='sideBarContent clearfix notepad hidden' id='tab_notePad'>
<div id='notepad'>
<div class='notepadInstructions'>
Click anywhere in Notepad to add a note.
</div>
<div class='protoNote note'>
<a class='anchor'></a>
<div class='headerRow'>
<div class='ieFloat'>
<span class='title'></span>
<span class='date'></span>
</div>
<div class='ieFloat right'>
<a class='delete'>
Delete
</a>
<div class='toolDivider'>
|
</div>
<a class='edit'>
Edit
</a>
</div>
<div class='clearfix'></div>
</div>
<div class='body'></div>
<div class='footer'>
<div class='ieFloat'>
<a class='previous'>
Previous
</a>
</div>
<div class='ieFloat pageDisplay'>
<span class='numNoteDisplay'></span>
</div>
<div class='ieFloat right'>
<a class='next'>
Next
</a>
</div>
</div>
</div>
<div class='protoNoteEditor note'>
<div class='headerRow'>
<div class='ieFloat'>
<span class='title'></span>
<span class='date'></span>
</div>
</div>
<div class='body'>
<textarea class='contents'></textarea>
<div class='toolRow'>
<a class='save'>
Save
</a>
<div class='toolDivider'>
|
</div>
<a class='cancel'>
Cancel
</a>
<div class='clearfix'></div>
</div>
</div>
<div class='footer'>
<div class='ieFloat'>
<a class='previous disabled'>
Previous
</a>
</div>
<div class='ieFloat pageDisplay'>
<span class='numNoteDisplay disabled'></span>
</div>
<div class='ieFloat right'>
<a class='next disabled'>
Next
</a>
</div>
</div>
</div>
<div class='protoConfirmDelete'>
<div class='popupWindowOuter'>
<div class='popupWindowInner'>
<div class='clearfix popupTitle'>
<div class='close' onclick='closePopup()'></div>
<h2>
Delete Note
</h2>
</div>
<div class='popupContent'>
<div class='sectionLabel'>
Are you sure you want to delete this note?
<br>
<br>
<br>
<br>
</div>
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right'>
<span>
Delete
</span>
</button>
<button class='bootstrap skinButton popup cancel right' onclick='closePopup()'>
<span>
Cancel
</span>
</button>
</div>
</div>
</div>
</div>
</div>

</div>
</div>

</div>
<div class='clearfix'></div>
</div>

<div class='keywordSearch' id='keyword_search'>
<a href="javascript:Blaw__findPrevKeyWord();redrawPrevNextButtons();" id="keyword_search_previous">Previous Keyword</a>
|
<a href="javascript:Blaw__findNextKeyWord();redrawPrevNextButtons();" id="keyword_search_next">Next Keyword</a>
</div>
<div class='pageLoader'></div>
<div class='browserPopupContainer' id='browserPopup'>
<div class='browserTitle'>
<div class='close' onclick='$("#browserPopup").bbTocBrowser(false);'></div>
<h2 class='popup_title'></h2>
</div>
<div class='browserPopupContent popup_content' id='browserPopupContent'></div>
</div>
<div class='maskOverlay' id='ajax_browser_mask'></div>


<div class='clearfix'></div>
</div>
</div>
<!-- _enter_client_matter.haml begin -->
<div class='clientMatterContainer hidden' id='clientMatterContainer'>
<form accept-charset="UTF-8" action="/client_matter/session/create" id="startClientMatterSessionForm" method="post"><div style="margin:0;padding:0;display:inline"><input name="utf8" type="hidden" value="&#x2713;" /><input name="authenticity_token" type="hidden" value="NiJ+70/qv61N1TFnbttr4ZzRa7IGhB5DMvou0CKGUXA=" /></div>
<input id="create_client_matter" name="create_client_matter" type="hidden" value="false" />
<div class='clearfix popupTitle'>
<div class='close' onclick='cancelClientMatterPopup()'></div>
<h2>
Enter a Client Matter
</h2>
</div>
<div class='popUpContent'>
<div class='clientMatterPopupHeader'>
Your firm optionally allows a client matter to be selected while you are using Bloomberg Law.
Please select from a recently used Client Matter or enter a Client Matter manually.
</div>
<div class='error' id='clientMatterLabelErrors' style='display:none'></div>
<div class='error' id='attorneyNumberLabelErrors' style='display:none'></div>
<div class='row sources clearfix'>
<div class='labelHolder'>
<span class='label'>Client Matter</span>
</div>
<div class='inputContainer'>
<input autocomplete="off" class="autocompleteTextField input_auto autocompleteForm" data-context="CLIENT_MATTERS" data-highlight-term="true" data-select-callback="applyClientMatterFromAutocompleteSelection" data-show-no-matches="false" data-url="/autocomplete/lookup" id="client_matter_label" name="client_matter_label" type="text" value="" />
<script type="text/javascript">
//<![CDATA[
jQuery().ready(function ($) { $('#client_matter_label').bbAutocomplete(); });
//]]>
</script>
</div>
</div>
<div class='row clientMatterSuppressionCheckholder' id='clientMatterSuppressionCheckholder'>
<label>
<input id="suppress_client_matter_prompt_enabled" name="suppress_client_matter_prompt_enabled" type="hidden" value="1" />
<input checked="checked" id="suppress_client_matter_prompt" name="suppress_client_matter_prompt" type="checkbox" value="1" />
<label for="suppress_client_matter_prompt">Do not remind me again this session</label>
</label>
</div>
<div class='clientMatterText'>
Please contact your administrator if you have questions about client matter.
</div>
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup right' type='submit'>
<span>
Submit
</span>
</button>
<button class='bootstrap skinButton popup cancel right' onclick='cancelClientMatterPopup();' type='button'>
<span>
Cancel
</span>
</button>
</div>
</form>

<div id='createClientMatterForm' style='display:none'>
<div class='clearfix popupTitle'>
<h2>
Unrecognized Client Matter
</h2>
</div>
<div class='div'>
Client Matter
<span id='new_client_matter_label'>&nbsp;</span>
does not currently exist in Bloomberg Law. Would you like to add this client matter to the system?
</div>
<div class='popUpActions'>
<button class='bootstrap skinButton popup action right' type='button'>
<span>
Yes
</span>
</button>
<button class='bootstrap skinButton popup cancel right' type='button'>
<span>
No
</span>
</button>
</div>
</div>
</div>
<!-- _enter_client_matter.haml begin -->

<div id='loading_container'></div>
<div class='fixedControls menuHolder printHide' id='bottom_menu_row'>
<div class='menuButton' id='pde_tray_menu'>
<div class='queueImageHolder'></div>
<div class='indicator num_of_pde_tray_items'></div>
</div>
<div class='clearfix'></div>
</div>
<div class='menuItem bottomMenu' id='pde_tray'>
<div class='inner'>
<div class='heading'>
<div class='title'>
Queue
<span class='indicator num_of_pde_tray_items'></span>
<!-- =pde_tray_count_from_session -->
</div>
<div class='bootstrap closeIcon right' id='pde_tray_close_button'></div>
<div class='clearfix'></div>
</div>
<div class='actions hasItems' id='pde_tray_has_items'>
<div class='selection'>
<div class='trayCheckHolder'>
<input id='pde_tray_select_all' type='checkbox'>
</div>
Select All
</div>
<div class='tools'>
<a onclick='javascript:PDETray_default.downloadSelection();'>
Print/Download
</a>
|
<a onclick='javascript:PDETray_default.emailSelection();'>
Email
</a>
|
<a onclick='javascript:PDETray_default.workspaceSelection();'>
+ Workspace
</a>
|
<a onclick='javascript:PDETray_default.deleteSelection();'>
Delete
</a>
</div>
<div class='clearfix'></div>
</div>
<div class='actions noItems' id='pde_tray_no_items'>
<div class='title'>
You have no items in your Queue
</div>
<div class='clearfix'></div>
</div>
<div class='itemsHolder' id='pde_tray_items'></div>
</div>
</div>

<div class='maskOverlay' id='pde_tray_mask'></div>

<script language='javascript'>
var SHOW_AUDIT = false;
var ROOT_PATH = "/";
var RAILS_ROOT = "/";
var CONTEXT_PATH = "/";
var DOC_ROOT_PATH = "/s/opinion/9e80f4ac7146e23390fa86e1f038dd82/";
var RESULTS_ROOT_PATH = "/search/results/";
var SELECTED_CONTEXT = "";
var MODULE_PATH;
MODULE_PATH = "/document";
var CRUMB_ID = "9e80f4ac7146e23390fa86e1f038dd82";
var BILLING_CONFIGURATION = {"DOCKET":true,"NEWS":false,"LAW":true,"ADVANCED_LEGAL":true,"PATENT":true,"PATENT_ASSIGNMENT":true,"PEOPLE":false,"OPINION":true,"CITATION":false,"BREAKING":true,"DOCKET_REQUESTS":true,"COMPANY_FILINGS_EDGAR":false,"COMPANY_FILINGS_DOCKETS":false,"COMPANY_FILINGS_OTHER":false,"CORP_ACTIONS":true,"ECO_SEARCH":true,"EDGAR_SEARCH":true,"EXAMPLE_DOCUMENTS":true,"CLAUSE_SEARCH":true,"LEG":true,"REG":true,"BOOLEAN":false,"SIMPLE":false,"COMPANY_DOCKETS":true,"TOC_SEARCH":true,"IMMUTABLE_LAW_SEARCH":true};
var CONTEXT_BILLING_POLICY_KEY = "";
var ELITE_ENABLED = false;
var CLIENT_MATTER_PROMPT_ENABLED = false;
var CLIENT_MATTER_ON_LOGIN_ENABLED = false;
var SUPPRESS_CLIENT_MATTER_PROMPT = false;
var clientMatterActive = false;
var currentClientMatter = '';
var currentAttorneyNumber = '';
var clientMatterHaltedForm = null;
var USER_ID = 'un=373038066';
var SESSION_ID = '63166_a5929cc15e1bfd637ed52768bec5d196';
var NTPT_REDIRECTED_EVENT = '';
var NTPT_PGEXTRA = '&activityType=ENTITY&subActivityType=DOCUMENT_VIEWED&pageId=&activityInstanceId=ENTITYb2de44&previousPageId=&previousActivityInstanceId=ENTITYc9c330&previousActivityType=ENTITY&previousSubActivityType=DOCUMENT_VIEWED&previousActivityTime=2014-02-02T01:00:46-05:00';
var NTPT_GLBLEXTRA = 'un=373038066&sessionId=63166_a5929cc15e1bfd637ed52768bec5d196&auth=true';
var BROWSER_COMPATIBILITY_WARNING = 'false';
var SHOW_MODAL = false;
var JUG;
$(document).ready(function(){
setTimeout(framework_getPageState,500);
framework_bindGlobalResizeElements();
notepad_onDocumentLoaded();
<!-- /DRQS 24932463 -->
$("#downloadPopupLinkForm a").removeAttr("href");
$('#startClientMatterSessionForm').submit(function() {
  createClientMatterSessionFromForm(this);
  return false;
});

var t = $('.clientMattersTableEl');

jQuery.each(t, function(name, value) {
  try {
    var this_value =  $.trim(String(value.innerHTML));
    var this_final_value = this_value.length > 22 ? this_value.substring(0,9)+"..." : this_value;
    value.innerHTML = this_final_value;
  } catch (e) {}
});

$('#startClientMatterSessionForm .recentlyUsed td').click(function() {
  $('#client_matter_label').val($.trim($(this).attr("title")));
});

});
</script>
<script type='text/javascript'>
DOCUMENT_SHOW_SIDEBAR="true";
DOCUMENT_HAS_SIDEBAR_INFO="true";
DOCUMENT_IS_IFRAME="";
NTPT_PGEXTRA = 'documentSearchType=OPINION&docId=X1I1772003&docType=OPINIONS&contentClass=LEGAL&activityType=ENTITY&subActivityType=DOCUMENT_VIEWED&pageId=&activityInstanceId=ENTITYc9c330&previousPageId=&previousActivityInstanceId=ENTITY4121d4&previousActivityType=ENTITY&previousSubActivityType=DOCUMENT_VIEWED&previousActivityTime=2014-02-02T01:00:34-05:00';
FLUID_LAYOUT="false";
FULL_DOC_ID = 'X1I1772003';
NOTEPAD_UUID="11082191";
NOTEPAD_DOC_ID="X1I1772003";
$('#page_loader').show().spin();
JUDGE_IDS=["1855226","3028474","3028536"];
JUDGE_NAMES=null;
</script>

<script src="/javascripts/activity_tracking/ni.js?1376494218" type="text/javascript"></script>
<script src="/javascripts/activity_tracking/tracking.js?1384975732" type="text/javascript"></script>
<div class='footer'>
<div class='footerContent printHide'>
<div class='logoContainer grid eight'>
<div class='copyright'>
&copy; 2014 The Bureau of National Affairs, Inc. All Rights Reserved.
 | 
<a href="#" class="menuLink" onclick="open_tos_or_privacy('X3BPR08'); return false;">Terms of Service</a>
 | 
<a href="#" class="menuLink" onclick="open_tos_or_privacy('X3BPH08'); return false;">Privacy Policy</a>
</div>
<a class='logo' href='/home'></a>
<div class='version'>
2.
231154
Gem
0.176.7
231497
 - 3.0.20
</div>
<div class='helpContainer'>
<div class='helpDesk'></div>
<a href="/help/BLAWHelpSystem.htm#Contact_Us.htm" class="menuLink">Submit Feedback</a>
 | 
<a href="mailto:blawhelp@bna.com" class="menuLink">blawhelp@bna.com</a>
</div>
</div>
</div>

</div>
</div>
</body>
</html>
